

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Feasibility and preliminary effects of tai chi for fatigue-sleep disturbance-depression symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048115
Article Type:	Protocol
Date Submitted by the Author:	23-Dec-2020
Complete List of Authors:	Yao, Li-Qun; Charles Darwin University, College of Nursing and Midwifery; Charles Darwin University Tan, Jing-Yu (Benjamin); Charles Darwin University, College of Nursing and Midwifery Brisbane Centre Turner, Catherine; Charles Darwin University, College of Nursing and Midwifery Wang, Tao ; Charles Darwin University, College of Nursing and Midwifery Brisbane Centre
Keywords:	Breast tumours < ONCOLOGY, COMPLEMENTARY MEDICINE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Feasibility and preliminary effects of tai chi for fatigue-sleep disturbance-depression symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled trial

Li-Qun Yao PhDc liqun.yao@students.cdu.edu.au

Charles Darwin University, College of Nursing and Midwifery, Ellengowan Drive, Darwin, NT 0909, Australia

Jing-Yu Tan PhD RN benjamin.tan@cdu.edu.au

Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11, 410 Ann Street, Brisbane, QLD 4000, Australia

Catherine Turner AM PhD RN catherine.turner@cdu.edu.au

Charles Darwin University, College of Nursing and Midwifery, Ellengowan Drive, Darwin, NT 0909, Australia

Tao Wang PhD alison.wang@cdu.edu.au

Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11, 410 Ann Street, Brisbane, QLD 4000, Australia

Correspondence

Associate Professor Jing-Yu Tan BNSc MMed PhD RN

Associate Professor in Nursing & Associate Dean Research

College of Nursing and Midwifery Brisbane Centre

Charles Darwin University

Level 11, 410 Ann Street, Brisbane, QLD 4000, Australia

Email: benjamin.tan@cdu.edu.au; Tel (Office): +61 7 3169 4269

Abstract

Introduction The fatigue-sleep disturbance-depression symptom cluster (FSDSC) is one of the most common and debilitating side effects in breast cancer (BC) patients throughout their treatment trajectory. Tai chi has been supported as a promising non-pharmacological intervention for the individual symptom management of cancer-related fatigue, sleep disturbance, and depression. However, relevant evidence of using tai chi for FSDSC management in BC patients has been lacking.

Methods This study will be a two-arm, single-blinded pilot randomized controlled trial (RCT) involving an 8-week intervention and a 4-week follow-up. Seventy-two BC patients experiencing the FSDSC will be recruited from two tertiary medical centres in China. The participants will be randomized to either a tai chi group (n=36) or a control group (n=36). The participants in the tai chi group will receive an 8-week tai chi intervention in addition to standard care, while the participants in the control group will receive standard care only consisting of a booklet on the self-management of cancer symptoms. The primary outcomes will include a series of feasibility assessments of the study protocol in relation to the study's methodological procedures, including subject recruitment and follow-up process, completion of study questionnaires, and the feasibility, acceptability, and safety of the intervention. The secondary outcomes will be the clinical outcomes regarding the effects of tai chi on the FSDSC and quality of life, which will be measured by the Brief Fatigue Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires.

Ethics and dissemination Ethics approval was obtained from the relevant sites (H19094, KY2019133, 201932). The findings of the study will be published in peer-reviewed scientific journals and at conferences.

Trail registration: ClinicalTrials.gov, identifier NCT04190342. Registered on 3 December 2019.

Keywords: Breast cancer; Fatigue; Sleep disturbance; Depression; Symptom cluster; Tai chi

Strengths and limitations of this study

- This will be the first clinical trial to explore the feasibility and preliminary effects of tai chi on FSDSC management in BC patients.
- This study will use an evidence-based tai chi intervention protocol in the intervention group which has been presented in a methodological paper.
- The study design of the pilot study will be guided by the Medical Research Council Framework for Developing and Evaluating Complex Interventions.
- This study will use comprehensive outcome measurements, including a series of feasibility outcomes, which will support the refinement of a clinically feasible tai chi intervention protocol for the future full-scale RCTs.
- There are limited study sites which may not provide a completely representative sample of BC patients who are experiencing the FSDSC.

Introduction

Breast cancer (BC) is regarded as the most common cancer among women worldwide [1]. Although the number of BC survivors is increasing with improved cancer treatment, the substantial negative effects associated with cancer and cancer treatments remain a significant problem for survivors. BC patients following the treatment of surgery, radiation therapy, antihormonal therapy, and/or chemotherapy can experience significant side effects, including fatigue, sleep disturbance, and depression [2]. These frequently reported, troublesome symptoms usually occur concurrently in BC patients as a symptom cluster [3, 4]. According to Dodd et al. [5], “a symptom cluster consists of three or more symptoms that are related to each other and that occur together” (p. 468). The fatigue-sleep disturbance-depression symptom cluster (FSDSC) is one of the most frequent symptom clusters among BC patients, which can negatively impact patients’ physical and psychosocial functioning status and quality of life (QoL), including more severe cancer-related symptoms, lower treatment compliance, poorer emotional conditions, worse financial hardship, and even shorter survival time [6-8].

To date, no specific medications are available for the management of cancer symptom clusters. Reviewing the previous evidence, various non-pharmacological approaches have been used as a combination treatment with medication for the comprehensive management of cancer-related symptoms [9-10]. However, most of the widely employed non-pharmacological approaches, such as acupuncture [11], hypnotherapy [12], guided imagery [13], massage [14], and electrical stimulation [15], require intensive professional skills training, supervised practise, and specific equipment, all of which can be significantly time- and energy-consuming and can considerably increase the consumption of healthcare resources and costs. Moreover, due to fatigue intolerance, cancer patients are usually reluctant to participate in energy-consuming non-pharmacological interventions such as intensive exercise [16]. Thus, an energy-saving and cost-effective non-pharmacological approach is much more appropriate for FSDSC management in cancer patients.

Traditional Chinese exercise (TCE) is an appropriate and effective option for FSDSC management in BC patients given its mild-to-moderate intensity and low cost. Tai chi, a very popular TCE, consists of several slow, simple, and repetitive body movements along with deep breathing, and it is easy to master [17]. Additionally, there has been increasing evidence of its positive effects in targeting the management of individual symptoms such as fatigue, sleep disturbance, and depression [18-20]. However, no clinical research has ever been performed using tai chi exercise for symptom cluster management, especially the FSDSC in BC patients. The current study therefore proposes to assess the feasibility and the preliminary effects of using an evidence-based tai chi intervention for managing the FSDSC in BC patients through a pilot randomized controlled trial (RCT).

Methods and materials

Study design

The study’s design will be a two-parallel-arm, single-blinded (assessor) pilot RCT. The participants will be randomly allocated into two groups: a tai chi intervention group and a control group, with an allocation ratio of 1:1. The study period will be 12 weeks, which will

involve an 8-week tai chi intervention and a 4-week follow-up for the intervention group. A CONSORT flowchart of the study is presented in **Figure 1**. The schedule of trial enrolment, intervention data collection, and assessments are presented in **Table 1**. This protocol will be reported in accordance with the SPIRIT Checklist.

Study setting

This study will be implemented in two tertiary medical centres in Mainland China, including the Affiliated Hospital of Putian University (Fujian) and the Affiliated Hospital of Southwest Medical University (Sichuan).

Sample size calculation

Thirty or more participants per group is usually recommended as sufficient for a pilot study to examine intervention feasibility [21] and to estimate a between-group effect for a subsequent power analysis that can be used in the main study's sample size estimation [22]. Given that the primary purpose of this study will be to explore the feasibility and acceptability of the study's methodological procedures, intervention protocol, and questionnaires, 30 participants per group is therefore an appropriate sample size in this study. Taking into account a conservative anticipation of a 20% dropout rate, the final sample size will therefore be 36 in each group, with a total of 72 participants [23].

Inclusion and exclusion criteria

Eligible participants will be recruited using the following inclusion criteria:

- (1) adult female patients aged over 18 years;
- (2) diagnosed with stage I, II, or IIIa BC (non-metastatic BC);
- (3) have experienced at least a moderate level of fatigue, sleep disturbance, and depression, with a score of greater than 3 on a 10-point scale, from "0 (no symptom)" to "10 (worst symptom)" for each symptom in the past one month;
- (4) have completed breast cancer surgery for over one month;
- (5) have recently commenced adjuvant chemotherapy;
- (6) able to speak and understand Mandarin Chinese; and
- (7) willing and able to give written informed consent for study participation.

Potential participants will be excluded using the following exclusion criteria:

- (1) presently taking medications for the treatment of fatigue, sleep disturbance, or depression, such as antidepressant medications, psychostimulants, or hypnotics;
- (2) extremely weak or have cognitive impairment and/or severe mental illness;
- (3) have participated in a tai chi program during the previous six months;
- (4) have practised other TCE for over 30 minutes, three times per week, during the previous three months; and
- (5) have scheduled other elective surgery within the trial period.

Recruitment

A research team will be formed before the commencement of the trial. Three investigators, including the doctoral investigator and two clinical nurses, will be primarily responsible for

1
2
3 the subject recruitment and tai chi training. Two research assistants will conduct data
4 collection and telephone follow-ups. To ensure the quality of data collection, the two research
5 assistants will be trained on questionnaire data collection skills, including understanding the
6 questionnaire items and standardizing their conversations with the participants. The academic
7 supervisors of the doctoral investigator will monitor the entire study procedure on an ongoing
8 basis through regular monthly meetings.
9
10

11
12 Among the hospitalized patients in the Breast Cancer Unit, potential participants will be
13 recruited directly by the doctoral investigator and the two clinical nurses. Some potential
14 participants who attend the breast cancer clinic for regular follow-ups will be referred by
15 physicians and clinic nurses to the doctoral investigator and the two clinical nurses. A
16 participant information sheet, including the research aim, the procedures, and the contact
17 details of the study investigators, will be given to potential participants and will be explained
18 by the doctoral investigator and the two clinical nurses. Potential participants who express
19 interest in participating in the study will be screened for eligibility with reference to the
20 inclusion and exclusion criteria by the doctoral investigator and the two clinical nurses. After
21 their agreement to participate, the participants will be required to provide their written
22 informed consent. The participants will be informed that they can withdraw from the study at
23 any moment without any consequences.
24
25
26
27
28

29 ***Randomization and allocation concealment***

30 One set of randomization sequences will be generated via an online randomizer
31 (<https://www.randomizer.org/>) based on the estimated sample size. To ensure allocation
32 concealment, the randomization sequences will be generated and retained by a statistician
33 who will not be involved in any other parts of this study. After the participants' completion of
34 the baseline assessment, the two clinical nurses will telephone the statistician to determine
35 which group the patient should be assigned. The participants will be randomly assigned to
36 either the tai chi intervention group or the control group.
37
38
39

40 ***Blinding***

41 Due to the visible nature of the tai chi intervention, the blinding of the study investigators and
42 the participants will be impossible. Thus, blinding will only be applied to the outcome
43 assessors (i.e., the two research assistants) in this pilot RCT to avoid potential detection bias
44 during data collection. The two research assistants will be responsible for data collection and
45 telephone follow-ups, and they will not be involved in the subject recruitment process.
46
47
48
49

50 ***Tai chi intervention group***

51 In addition to the standard care provided to both the control group and the intervention group,
52 the participants in the intervention group will additionally receive instruction on easy 8 form
53 tai chi movements. The development and validation of the evidence-based tai chi intervention
54 protocol are detailed in a methodological paper [24]. The intervention regime will last 60
55 minutes per session, two sessions per week, for eight weeks, which is based on existing
56 research evidence, theories, practice standards/guidelines, and experts' consensus [24]. To
57 ensure that the patients have fully mastered the tai chi skills, before the commencement of the
58
59
60

1
2
3 intervention, the participants will receive at least three 60-minute training sessions until they
4 can perform the movements correctly and smoothly, along with a home learning package in
5 an audio-visual format (i.e., a recorded video). The training will be conducted and led by
6 either the doctoral investigator or the two clinical nurses, and attendance will be recorded. All
7 the participants will be asked to perform the tai chi movements in front of the trainers (i.e.,
8 return demonstration) to make sure that they are correctly performing each movement of the
9 tai chi exercise. In addition, the participants will be tested by the trainers during the last
10 training session to ensure that they have correctly performed the tai chi movements (a “return
11 demonstration”).
12
13
14

15
16 Easy 8 form tai chi is comprised of the following components: a 10-minute warm-up, 25 to 30
17 minutes of easy tai chi practising, and a 10-minute cool-down. During each session, the
18 participants will also have a 10-minute break to rest and interact socially. Details of the tai chi
19 protocol are presented in a methodological paper [24]. A specially designed exercise log will
20 be provided to the participants to record information related to their tai chi practice each time,
21 such as duration and frequency of practising tai chi, as well as any potential adverse reactions
22 related to tai chi, such as dizziness, knee pain, musculoskeletal aches and pains, etc. The
23 exercise logs will be returned to the research assistants on the date of the participants’
24 treatment or follow-up appointment at the hospital. To enhance the participants’ adherence to
25 the tai chi intervention, the research assistants will conduct follow-ups every week using
26 WeChat (the most popular social media platform in China) or phone calls to remind them to
27 practise their tai chi and to collect information on any potential adverse reactions related to
28 the tai chi intervention.
29
30
31
32

33 ***Control group***

34
35 The participants allocated to the control group will receive a standard care package, which
36 will be a booklet on the self-management of cancer symptoms. This booklet will offer basic
37 knowledge and management strategies regarding FSDSC management in BC patients during
38 or after chemotherapy treatment. All the information listed in this booklet will be
39 comprehensively adapted from relevant national guidelines developed by professional
40 associations in cancer care and government health department websites, including the
41 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
42 (the NCCN Guidelines) [25] and the Department of Health – Government of Western
43 Australia [26]. Research evidence in published peer-reviewed articles will also be cited as
44 supporting information for the booklet’s development [2, 27-29]. Additionally, the
45 participants will be asked to refrain from practising any exercises related to TCE during the
46 study, with reminders at all assessment time points. On completion of the pilot RCT, the
47 participants in the control group will have an opportunity to receive the tai chi training from
48 the study team.
49
50
51
52
53

54 ***Outcome measurements and follow-up***

55
56 The outcome measurements for this pilot RCT will include three categories, namely, baseline
57 assessments, feasibility and acceptability outcomes, and clinical outcomes. The feasibility and
58 acceptability outcomes will be the primary outcomes, while the clinical outcomes will be the
59
60

secondary outcomes. All the outcomes and follow-ups will be conducted by the two research assistants.

Demographic and clinical characteristics of the participants

A self-designed demographic and clinical data form will be employed to collect the participants' socio-demographic data (e.g., age, education background, employment status, marital status, and household income) and medical history (e.g., date of diagnosis, the current stage of BC, and date and type of treatment) at baseline (T1).

Primary outcomes: Feasibility and acceptability

(1) The feasibility assessment of subject recruitment and follow-up process will include: (a) the time that was taken to recruit the planned sample size of participants; (b) referral rate – the number of referrals made by clinicians in different departments and hospitals divided by all referrals; (c) recruitment rate – the number of subjects who enrolled in the study divided by all subjects eligible for enrolment; (d) retention rate – the number of subjects who completed the study divided by all subjects who enrolled in the study; (e) dropout rate – the number of subjects who dropped out after randomization divided by all subjects who enrolled in the study; and (f) feedback from the dropout subjects to identify their reasons for dropping out. The feasibility of recruitment and follow-up process outcomes will be collected at baseline (T1) and immediately after the intervention (T2).

(2) The feasibility assessment of the outcome measures will include the percentage of missing values for each item of the scales used – the Brief Fatigue Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS), and the Functional Assessment of Cancer Therapy-Breast (FACT-B) – at baseline (T1), immediately after the intervention (T2), and four weeks after completion of the intervention (T3).

(3) The feasibility and acceptability of the intervention will include: (a) adherence rates – the number of tai chi sessions practised divided by the total number of sessions required; (b) the participants' feedback on and satisfaction with the intervention using a self-designed feedback form; and (c) records of potential adverse events associated with tai chi, which will be obtained from the exercise log. The feasibility and acceptability of the intervention will be assessed immediately after the intervention (T2).

Secondary outcomes: Fatigue, sleep disturbance, depression, and QoL

The fatigue, sleep disturbance, depression, and QoL of the BC patients as the secondary outcomes will be measured at T1, T2, and T3 using the BFI, the PSQI, the HADS, and the FACT-B.

(1) Fatigue: The participants' severity of fatigue and cancer-related fatigue in daily functioning will be assessed using the BFI. The BFI has nine items, with higher scores corresponding to more severe fatigue [30, 31]. The Chinese version of the BFI has excellent internal consistency reliability (Cronbach's alpha from 0.90 to 0.92), as well as construct validity and convergent validity [32].

1
2
3 (2) Sleep disturbance: The participants' sleep quality and disturbance will be assessed using
4 the PSQI. This questionnaire has seven domains: sleep latency, habitual sleep efficiency,
5 subjective sleep quality, sleep duration, use of sleeping medication, sleep disturbance, and
6 daytime dysfunction [33]. The Chinese version of the PSQI has been demonstrated to be a
7 reliable and valid scale, and it has been widely utilized among cancer patients [34].
8
9

10 (3) Depression: The HADS will be used to assess the participants' depression. The cut-off
11 scores have been classified and labelled as 0 to 7 for "normal", 8 to 10 for "mild", 11 to 15
12 for "moderate", and ≥ 16 for "severe" [35]. As a reliable and valid tool for measuring
13 depression, the HADS has been widely utilized among Chinese cancer patients, with
14 well-documented psychometric properties [36].
15
16

17 (4) Quality of life: The FACT-B will be adopted to assess the participants' QoL. A higher
18 score demonstrates better QoL. The FACT-B is available in a simplified Chinese version,
19 with adequate psychometric properties reported among patients with BC [37].
20
21
22

23 **Data management**

24 The doctoral investigator and one of the research assistants will enter all the collected data
25 into a computer with a double data entry approach. To ensure that there are no discrepancies
26 or coding errors after running descriptive and inferential statistics, data cleaning will be
27 conducted before data analysis [38]. First, the datasets will be checked against the paper
28 recordings of raw data to ensure that the data coding is correct. Then, double-checking will be
29 undertaken by the other research assistant to ensure accuracy. All electronic data will be
30 retained in a compressed folder using password-protected access systems, and all hard copies
31 of the materials will be retained in a cabinet at the study sites. Storage and disposal of
32 research data hard copies will strictly follow the regulations and policies of the lead
33 investigator's institution and the study sites, including the Charles Darwin University
34 Research Data Management Guide.
35
36
37
38

39 **Data analysis**

40 Statistical analyses will be conducted using IBM SPSS Statistics for Windows, version 24.0
41 (IBM Corp., Armonk, NY, USA). The intention-to-treat (ITT) principle and the last
42 observation carried forward (LOCF) method will be utilized for the management of missing
43 data. Effect sizes (ES) of between-group comparisons will be estimated using Cohen's d [39].
44 The chi-squared test or Fisher's exact test will be used to examine the comparisons between
45 the control and intervention groups for categorical variables (e.g., education background,
46 referral rate, retention rate, etc.). An independent t-test or the Mann-Whitney U test will be
47 utilized for the continuous variables (e.g., age, household income, etc.). The Generalized
48 Estimating Equation (GEE) model will be performed for repeated multivariate analysis
49 between the two study groups for the scores and domain scores of the BFI, the PSQI, the
50 HADS, and the FACT-B. The significance level to identify statistical differences will be
51 $p < 0.05$.
52
53
54
55
56
57

58 **Patient and public involvement**

No patient involved in the study design or any other part of this protocol.

Ethics and dissemination

This study was registered at ClinicalTrials.gov (identifier NCT04190342) before its commencement. The study has been approved by the Human Research Ethics Committee at Charles Darwin University (H19094), the Clinical Trial Ethics Committee at the Affiliated Hospital of Southwest Medical University (KY2019133), and the Clinical Trial Ethics Committee at the Affiliated Hospital of Putian University (201932). The abstract of this study has been submitted to Sigma's 32nd International Nursing Research Congress for presentation in 2021. The results of the study will be published in peer-reviewed scientific journals.

Discussion

As one of the most common symptom clusters in BC patients, the FSDSC can significantly deteriorate patients' QoL and daily functioning [40,41]. An increasing number of studies have demonstrated that tai chi has beneficial effects on symptom management in cancer patients; however, almost all the studies focused on individual symptoms only, such as fatigue, sleep disturbance, and depression [42-44]. No study has ever been performed to investigate the role of tai chi in managing symptom clusters in the BC population. This highlights a great need to explore the effects of tai chi on the FSDSC in BC patients. Given that the patients will have already experienced fatigue upon enrolment in this pilot RCT, lengthy and complicated tai chi movements will be avoided. Easy 8 form tai chi, a traditional Chinese mind-body exercise with only eight simple movements, is an appropriate intervention for FSDSC management as it is easy to learn, is less energy-consuming, and requires no specific equipment [45,46].

This study has some strengths. According to the Medical Research Council Framework for Developing and Evaluating Complex Interventions, the feasibility and acceptability of a proposed intervention and research methodological procedures should be fully examined prior to performing the full-scale study [47]. In this current pilot RCT, the feasibility and acceptability of an easy 8 form tai chi intervention program will be assessed comprehensively using a series of feasibility outcomes, including subject recruitment, intervention delivery, and outcome assessments. A comprehensive assessment will promote the refinement of the intervention protocol for the future main study. Furthermore, different from some current non-pharmacological studies, the tai chi intervention protocol used in the current pilot RCT will be evidence-based and rigorously developed based on systematic review evidence and recommendations [48-56]; TCE principles, theories [57, 58], and practice standards [46, 59]; the characteristics of cancer-related symptoms; and the consensus of an expert panel. In addition, an FSDSC self-management education booklet will be designed and provided to the participants in both the intervention and control groups. The information listed in this booklet will be comprehensively adapted from relevant national guidelines, professional bodies, and research evidence in published peer-reviewed articles. The self-management education booklet will be used as an enhanced care component to improve the patients' knowledge and relevant coping strategies for FSDSC management. Finally, a safety assessment of the tai chi protocol for cancer patients will be set as one of the feasibility outcomes, which has rarely been measured in existing tai chi interventional studies. Although tai chi is a non-invasive intervention that is generally regarded as a relatively safe approach, the exercise program

1
2
3 might still contribute to some minor adverse events such as a lumbar sprain, musculoskeletal
4 aches and pains, dizziness, knee pain, etc. [60]. Therefore, any potential adverse events
5 related to practising tai chi will be monitored and reported in the exercise log.
6
7

8 This study also has some limitations. Given the limited study sites, the study sample in this
9 study may not offer a completely representative sample of BC patients who are experiencing
10 the FSDSC. Due to the visible nature of the tai chi intervention, the blinding of the
11 participants and the tai chi instructor cannot be performed in this study, which might increase
12 the risk of detection bias during the study's implementation, although the outcome assessors
13 will be blinded to the intervention allocation. The lack of long-term follow-up to assess the
14 ongoing effects of tai chi might be another limitation, but this can be considered in the future
15 full-scale RCT as one of the main study outcomes.
16
17
18

19 This study will utilize a rigorously designed RCT to assess the feasibility and preliminary
20 effects of an evidence-based tai chi intervention program for managing the FSDSC in BC
21 patients. Findings from this study will provide a significant knowledge and evidence base for
22 cancer symptom management. The convenience of the tai chi intervention for the
23 self-management of the FSDSC may provide BC patients, healthcare professionals, and
24 policymakers with further guidance in FSDSC management in the long run. Furthermore, the
25 results of this trial will contribute to a future multi-centre large-scale main RCT to further
26 conclude the research evidence on the effects and safety of tai chi for FSDSC management in
27 BC patients. Specially, the results regarding the primary outcomes will provide evidence on
28 the feasibility issues of the tai chi intervention protocol and the methodological procedures of
29 the RCT. The results regarding the effect size estimations of the outcome parameters in this
30 pilot RCT will also be utilized for sample size estimation in the future main RCT.
31
32
33
34
35
36

37 **Conclusion**

38 The research design and methodological procedures of the proposed assessor-blinded pilot
39 RCT aim to assess the feasibility and preliminary effects of using an evidence-based tai chi
40 intervention to manage the FSDSC in BC patients. The results of this pilot study will provide
41 research evidence in terms of the feasibility and acceptability of using the evidence-based tai
42 chi intervention for FSDSC management in BC patients, as well as contribute to the
43 refinement of the tai chi intervention protocol, which will be utilized in a future multi-centre
44 large-scale RCT to determine the definite effects of tai chi on the FSDSC in BC patients.
45
46
47

48 **Trial status**

49 The study began in May 2020. Recruitment is ongoing. The study is expected to be completed
50 in May 2021.
51

52 **Funding**

53 This study was supported by the Australian Government Research Training Program (RTP)
54 scholarship.
55
56

57 **Conflict of interest**

1
2
3 The authors declare that there is no conflict of interest in terms of the publication of this
4 paper.
5
6

7 **Authors' contribution**

8 **Yao LQ:** study conception and design, trial organization, administration and coordination,
9 quality assurance, and manuscript drafting and revision; **Tan JY:** study conception and design,
10 study procedure supervision, and manuscript revision; **Turner C:** study conception and
11 design, study procedure supervision, and manuscript revision; **Wang T:** study design, study
12 procedure supervision, and manuscript revision.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. The schedule of trial enrolment, interventions, and assessments

	Study Period				
	Before Enrolment (0 weeks)	Intervention Period (1-8 weeks)	End of Intervention (8 weeks)	Follow-up Period (9-12 weeks)	End of Follow-up (12 weeks)
Inclusion/exclusion criteria	×				
Informed consent	×				
Demographic characteristics	×				
Randomization and allocation	×				
Feasibility of recruitment and follow-up process	×		×	×	×
Feasibility assessment of the outcome measures	×		×		×
Feasibility and acceptability of the intervention		×			
BFI	×		×		×
HADS	×		×		×
PSQI	×		×		×
FACT-B	×		×		×
Safety measurement		×			

1
2
3
4
5 **Figure 1.** A CONSORT flowchart of the study
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

- [1] Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol*. 2019 May 1;30(5):781-787. doi: 10.1093/annonc/mdz051.
- [2] Jain S, Boyd C, Fiorentino L, Khorsan R, Crawford C. Are there efficacious treatments for treating the fatigue-sleep disturbance-depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL(©)). *Breast Cancer (Dove Med Press)*. 2015 Sep 2;7:267-91. doi: 10.2147/BCTT.S25014.
- [3] Hsu HT, Lin KC, Wu LM, Juan CH, Hou MF, Hwang SL, Liu Y, Dodd MJ. Symptom Cluster Trajectories During Chemotherapy in Breast Cancer Outpatients. *J Pain Symptom Manage*. 2017 Jun;53(6):1017-1025. doi: 10.1016/j.jpainsymman.2016.12.354.
- [4] Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. *Sleep*. 2012 Feb 1;35(2):237-45. doi: 10.5665/sleep.1630.
- [5] Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum*. 2001 Apr;28(3):465-70.
- [6] Aktas A, Kirkova J, Walsh D, Karafa M, Nair A, Schleckman E. The psychometric properties of cancer multi-symptom assessment instruments: A comprehensive review. *J Pain Symptom Manage* 2012;43(2):334-5.
- [7] Ho SY, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. *J Pain Symptom Manage*. 2015 Apr;49(4):707-15. doi: 10.1016/j.jpainsymman.2014.09.009.
- [8] Kim HJ, Barsevick AM, Beck SL, Dudley W. Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer: a secondary analysis. *Oncol Nurs Forum*. 2012 Jan;39(1):E20-30. doi: 10.1188/12.ONF.E20-E30.
- [9] Hökkä M, Kaakinen P, Pölkki T. A systematic review: non-pharmacological interventions in treating pain in patients with advanced cancer. *J Adv Nurs*. 2014 Sep;70(9):1954-1969. doi: 10.1111/jan.12424.
- [10] Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: a systematic review of non-pharmacological interventions. *Int J Nurs Pract*. 2014 Oct;20(5):549-60. doi: 10.1111/ijn.12211.
- [11] Yin C, Buchheit TE, Park JJ. Acupuncture for chronic pain: an update and critical overview. *Curr Opin Anaesthesiol*. 2017 Oct;30(5):583-592. doi: 10.1097/ACO.0000000000000501.
- [12] McKernan LC, Finn MTM, Patterson DR, Williams RM, Jensen MP. Clinical Hypnosis for Chronic Pain in Outpatient Integrative Medicine: An Implementation and Training Model. *J Altern Complement Med*. 2020 Feb;26(2):107-112. doi: 10.1089/acm.2019.0259.
- [13] Charalambous A, Giannakopoulou M, Bozas E, Marcou Y, Kitsios P, Paikousis L. Guided Imagery And Progressive Muscle Relaxation as a Cluster of Symptoms Management Intervention in Patients Receiving Chemotherapy: A Randomized Control Trial. *PLoS One*. 2016 Jun

- 24;11(6):e0156911. doi: 10.1371/journal.pone.0156911.
- [14] Lopez G, Liu W, Milbury K, Spelman A, Wei Q, Bruera E, Cohen L. The effects of oncology massage on symptom self-report for cancer patients and their caregivers. *Support Care Cancer*. 2017 Dec;25(12):3645-3650. doi: 10.1007/s00520-017-3784-7.
- [15] Nguyen LT, Yates P, Annoussamy LC, Truong TQ. The effectiveness of non-pharmacological interventions in the management of symptom clusters in adult cancer patients: a systematic review protocol. *JBI Database System Rev Implement Rep*. 2016 Apr;14(4):49-59. doi: 10.11124/JBISRIR-2016-2476.
- [16] Zou L, Wang H, Xiao Z, Fang Q, Zhang M, Li T, Du G, Liu Y. Tai chi for health benefits in patients with multiple sclerosis: A systematic review. *PLoS One*. 2017 Feb 9;12(2):e0170212. doi: 10.1371/journal.pone.0170212.
- [17] Jahnke R, Larkey L, Rogers C, Etnier J, Lin F. A comprehensive review of health benefits of qigong and tai chi. *Am J Health Promot*. 2010 Jul-Aug;24(6):e1-e25. doi: 10.4278/ajhp.081013-LIT-248.
- [18] Irwin MR, Olmstead R, Carrillo C, Sadeghi N, Nicassio P, Ganz PA, Bower JE. Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial. *J Clin Oncol*. 2017 Aug 10;35(23):2656-2665. doi: 10.1200/JCO.2016.71.0285. Epub 2017 May 10. Erratum in: *J Clin Oncol*. 2017 Dec 20;35(36):4096.
- [19] McQuade JL, Prinsloo S, Chang DZ, Spelman A, Wei Q, Basen-Engquist K, Harrison C, Zhang Z, Kuban D, Lee A, Cohen L. Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial. *Psychooncology*. 2017 Nov;26(11):1936-1943. doi: 10.1002/pon.4256.
- [20] Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai Chi Exercise for Cancer-Related Fatigue in Patients With Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial. *J Pain Symptom Manage*. 2016 Mar;51(3):504-11. doi: 10.1016/j.jpainsymman.2015.11.020.
- [21] Browne, RH. On the use of a pilot sample for sample size determination. *Statistics in medicine*,1995;14(17), 1933-1940.
- [22] Hertzog MA. Considerations in determining sample size for pilot studies. *Res Nurs Health*. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247.
- [23] Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY. Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. *Integr Cancer Ther*. 2013 Nov;12(6):464-74. doi: 10.1177/1534735413485418.
- [24] Yao LQ, Tan JY, Turner C, Wang T. Development and Validation of a Tai Chi Intervention Protocol for Managing the Fatigue-Sleep Disturbance-Depression Symptom Cluster in Female Breast Cancer Patients. *Complementary Therapies in Medicine (In press)*.
- [25] NCCN Cancer-Related Fatigue Panel (2018). National Comprehensive Cancer Network Clinical practice guidelines in oncology. Cancer-Related Fatigue, version 2.
- [26] Department of Health at the Government of Western Australia. Retrieved from

1
2
3
4 <https://www.health.gov.au/resources>.

5 [27] Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C,
6 Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA,
7 Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS,
8 Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C; National
9 comprehensive cancer network. Cancer-Related Fatigue, Version 2.2015. J Natl Compr Canc
10 Netw. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122.

11 [28] Berger AM, Mitchell SA, Jacobsen PB, Pirl WF. Screening, evaluation, and management of
12 cancer-related fatigue: Ready for implementation to practice? CA Cancer J Clin. 2015
13 May-Jun;65(3):190-211. doi: 10.3322/caac.21268.

14 [29] Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer.
15 J Clin Oncol. 2012 Apr 10;30(11):1187-96. doi: 10.1200/JCO.2011.39.7372.

16 [30] Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The
17 rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer.
18 1999 Mar 1;85(5):1186-96. doi: 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cnrcr24>3.0.
19 co;2-n.

20 [31] Nunes AF, Bezerra CO, Custódio JDS, Friedrich CF, Oliveira IS, Lunardi AC. Clinimetric
21 Properties of the Brief Fatigue Inventory Applied to Oncological Patients Hospitalized for
22 Chemotherapy. J Pain Symptom Manage. 2019 Feb;57(2):297-303. doi:
23 10.1016/j.jpainsymman.2018.10.508.

24 [32] Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS. Validation study
25 of the Chinese version of the Brief Fatigue Inventory (BFI-C). J Pain Symptom Manage. 2004
26 Apr;27(4):322-32. doi: 10.1016/j.jpainsymman.2003.09.008.

27 [33] Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep
28 Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989
29 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

30 [34] Tsai PS, Wang SY, Wang MY, Su CT, Yang TT, Huang CJ, Fang SC. Psychometric
31 evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary
32 insomnia and control subjects. Qual Life Res. 2005 Oct;14(8):1943-52. doi:
33 10.1007/s11136-005-4346-x.

34 [35] Smith RP., Zigmond AS. The hospital anxiety and depression scale manual. Windsor:
35 NFER--Nelson.1994.

36 [36] Wang W, Chair SY, Thompson DR, Twinn SF. A psychometric evaluation of the Chinese
37 version of the Hospital Anxiety and Depression Scale in patients with coronary heart disease. J
38 Clin Nurs. 2009 Jul;18(13):1908-15. doi: 10.1111/j.1365-2702.2008.02736.x.

39 [37] Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X. Validation of the
40 simplified Chinese version of the FACT-B for measuring quality of life for patients with breast
41 cancer. Breast Cancer Res Treat. 2007 Dec;106(3):413-8. doi: 10.1007/s10549-007-9511-1.

42 [38] Portney LG, Watkins MP. Foundations of clinical research: applications to practice (Vol.
43

- 892). Upper Saddle River, NJ: Pearson/Prentice Hall. 2009.
- [39] Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*; Lawrence Earlbaum Associate: Hillsdale, NJ, USA, 1988.
- [40] Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G. The relationship between depression and physical symptom burden in advanced cancer. *BMJ Support Palliat Care*. 2015 Dec;5(4):381-8. doi: 10.1136/bmjspcare-2012-000380.
- [41] Oh H, Seo Y, Jeong H, Seo W. The identification of multiple symptom clusters and their effects on functional performance in cancer patients. *J Clin Nurs*. 2012 Oct;21(19-20):2832-42. doi: 10.1111/j.1365-2702.2011.04057.x.
- [42] Qiang WM, Dong FQ, Yan L, et al. Comparison of two different exercise programs in breast cancer patients after postoperative adjuvant chemotherapy. *Chin J Nurs*. 2011; 46:537e540.
- [43] Jiang MY. Influence of shadowboxing on improving cancer-related fatigue and sleeping quality of patients with advanced lung cancer. *Chin Nurs Res*. 2013;27:420e421.
- [44] Larkey LK, Roe DJ, Weihs KL, Jahnke R, Lopez AM, Rogers CE, Oh B, Guillen-Rodriguez J. Randomized controlled trial of Qigong/Tai Chi Easy on cancer-related fatigue in breast cancer survivors. *Ann Behav Med*. 2015 Apr;49(2):165-76. doi: 10.1007/s12160-014-9645-4. PMID: 25124456; PMCID: PMC4329282.
- [45] Tadros G, Ormerod S, Dobson-Smyth P, Gallon M, Doherty D, Carryer A, Oyeboode J, Kingston P. The management of behavioural and psychological symptoms of dementia in residential homes: does Tai Chi have any role for people with dementia? *Dementia (London)*. 2013 Mar;12(2):268-79. doi: 10.1177/1471301211422769.
- [46] Li F, Fisher KJ, Harmer P, Shirai M. A simpler eight-form easy tai chi for elderly adults. *Journal of Aging and Physical Activity*. 2003. 11(2), 206-218.
- [47] Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ*. 2008 Sep 29;337:a1655. doi: 10.1136/bmj.a1655.
- [48] Ma HL, Tan JY, Yang LH, Tao L, QJ. Current Evidence on Traditional Chinese Exercises for Cancer-Related Fatigue: A Quantitative Synthesis of Randomized Controlled Trials. *Eur J Integr Med*. 2016; 8(5):707-714. doi:10.1016/j.eujim.2016.05.007.
- [49] Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, Song R. Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. *J Cancer Surviv*. 2018 Apr;12(2):256-267. doi: 10.1007/s11764-017-0665-5.
- [50] Song S, Yu J, Ruan Y, Liu X, Xiu L, Yue X. Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials. *Support Care Cancer*. 2018 Jul;26(7):2091-2102. doi: 10.1007/s00520-018-4136-y.
- [51] Van Vu D, Molassiotis A, Ching SSY, Le TT. Effects of Qigong on symptom management in cancer patients: A systematic review. *Complement Ther Clin Pract*. 2017 Nov;29:111-121. doi: 10.1016/j.ctcp.2017.09.005.
- [52] Xiang Y, Lu L, Chen X, Wen Z. Does Tai Chi relieve fatigue? A systematic review and

1
2
3 meta-analysis of randomized controlled trials. *PLoS One*. 2017 Apr 5;12(4):e0174872. doi:
4 10.1371/journal.pone.0174872.

5
6 [53] Yao LQ, Tan JY, Turner C, Wang T, Liu XL. Traditional Chinese exercise for cancer-related
7 sleep disturbance: a systematic review and descriptive analysis of randomized clinical trials.
8 *Complement Ther Clin Pract*. doi:10.1016/j.ctcp.2020.101197.

9
10 [54] Zeng Y, Xie X, Cheng ASK. Qigong or Tai Chi in Cancer Care: an Updated Systematic
11 Review and Meta-analysis. *Curr Oncol Rep*. 2019 Apr 6;21(6):48. doi:
12 10.1007/s11912-019-0786-2.

13
14 [55] Ni X, Chan RJ, Yates P, Hu W, Huang X, Lou Y. The effects of Tai Chi on quality of life of
15 cancer survivors: a systematic review and meta-analysis. *Support Care Cancer*. 2019
16 Oct;27(10):3701-3716. doi: 10.1007/s00520-019-04911-0.

17
18 [56] Hilfiker R, Meichtry A, Eicher M, Nilsson Balfe L, Knols RH, Verra ML, Taeymans J.
19 Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during
20 or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis.
21 *Br J Sports Med*. 2018 May;52(10):651-658. doi: 10.1136/bjsports-2016-096422.

22
23 [57] Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: A
24 descriptive review. *Brain Behav Immun*. 2016 Jan;51:1-11. doi: 10.1016/j.bbi.2015.06.012.

25
26 [58] Larkey L, Jahnke R, Etnier J, Gonzalez J. Meditative movement as a category of exercise:
27 implications for research. *J Phys Act Health*. 2009 Mar;6(2):230-8. doi: 10.1123/jpah.6.2.230.

28
29 [59] Committee of Chinese Sports College Textbook Chinese wushu textbook (Part I)
30 People's Sports Publishing House of China, Beijing, 2003.

31
32 [60] Jia X, Jiang C, Tao J, Li Y, Zhou Y, Chen LD. Effects of core strength training
33 combined with Tai Chi Chuan for the musculoskeletal system and cardiopulmonary function
34 in older adults: A study protocol for a randomized controlled trial. *Medicine (Baltimore)*.
35 2018 Aug;97(35):e12024. doi: 10.1097/MD.00000000000012024.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. A CONSORT flowchart of the study

BMJ Open

Feasibility and potential effects of tai chi for the fatigue-sleep disturbance-depression symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048115.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jul-2021
Complete List of Authors:	Yao, Li-Qun; Charles Darwin University, College of Nursing and Midwifery Brisbane Centre Tan, Jing-Yu (Benjamin); Charles Darwin University, College of Nursing and Midwifery Brisbane Centre Turner, Catherine; Charles Darwin University, College of Nursing and Midwifery Brisbane centre Wang, Tao ; Charles Darwin University, College of Nursing and Midwifery Brisbane Centre
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Nursing, Oncology
Keywords:	Breast tumours < ONCOLOGY, COMPLEMENTARY MEDICINE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Title Page**
5

6 2 Feasibility and potential effects of tai chi for the fatigue-sleep disturbance-depression
7 3 symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled
8 4 trial
9
10
11 5

12 6 **Li-Qun Yao** PhD liqun.yao@students.cdu.edu.au

13 7 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
14 8 410 Ann Street, Brisbane, QLD 4000, Australia

15 9 **Jing-Yu (Benjamin) Tan** PhD RN benjamin.tan@cdu.edu.au

16 10 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
17 11 410 Ann Street, Brisbane, QLD 4000, Australia

18 12 **Catherine Turner** AM PhD RN catherine.turner@cdu.edu.au

19 13 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
20 14 410 Ann Street, Brisbane, QLD 4000, Australia

21 15 **Tao Wang** PhD alison.wang@cdu.edu.au

22 16 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
23 17 410 Ann Street, Brisbane, QLD 4000, Australia
24 18

25 19 Correspondence

26 20 **Associate Professor Jing-Yu (Benjamin) Tan** PhD RN

27 21 Associate Professor in Nursing & Associate Dean Research

28 22 College of Nursing and Midwifery Brisbane Centre

29 23 Charles Darwin University

30 24 Level 11, 410 Ann Street, Brisbane, QLD 4000, Australia

31 25 Email: benjamin.tan@cdu.edu.au; Tel (Office): +61 7 3169 4269
32 26
33 27
34 28
35 29
36 30
37 31
38 32
39 33
40 34
41 35
42 36
43 37
44 38

1 Abstract

2 **Introduction** The fatigue-sleep disturbance-depression symptom cluster (FSDSC) is one of
3 the most common and debilitating side effects in breast cancer (BC) patients throughout their
4 treatment trajectory. Tai chi has been supported as a promising non-pharmacological
5 intervention for the individual symptom relief of cancer-related fatigue, sleep disturbance, and
6 depression. However, relevant evidence of using tai chi for FSDSC management in BC
7 patients has been lacking.

8
9 **Methods** This study will be a two-arm, single-blinded pilot randomized controlled trial (RCT)
10 involving an 8-week intervention and a 4-week follow-up. Seventy-two BC patients
11 experiencing the FSDSC will be recruited from two tertiary medical centres in China. The
12 participants will be randomized to either a tai chi group (n=36) or a control group (n=36). The
13 participants in the tai chi group will receive an 8-week tai chi intervention in addition to
14 standard care, while the participants in the control group will receive standard care only
15 consisting of a booklet on the self-management of cancer symptoms. The primary outcomes
16 will include a series of feasibility assessments of the study protocol in relation to the study's
17 methodological procedures, including subject recruitment and follow-up process, completion
18 of study questionnaires, and the feasibility, acceptability, and safety of the intervention. The
19 secondary outcomes will be the clinical outcomes regarding the effects of tai chi on the
20 FSDSC and quality of life, which will be evaluated by the Brief Fatigue Inventory (BFI), the
21 Pittsburgh Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS),
22 and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires.

23
24 **Ethics and dissemination** Ethics approval was obtained from relevant sites (H19094,
25 KY2019133, 201932). The findings of the study will be published in peer-reviewed scientific
26 journals and at conferences.

27
28 **Trail registration:** ClinicalTrials.gov, identifier NCT04190342. Registered on 3 December
29 2019.

30
31 **Keywords:** Breast cancer; Fatigue; Sleep disturbance; Depression; Symptom cluster; Tai chi

32 **Strengths and limitations of this study**

- 33 ● This will be the first clinical study to explore the feasibility and preliminary effects of tai
34 chi on FSDSC management in BC patients.
- 35 ● This study will use an evidence-based tai chi protocol in the intervention group which
36 was comprehensively developed based on best available research evidence, guidelines,
37 theories, and practice standards.
- 38 ● The design of the pilot study will be guided by the Medical Research Council
39 Framework for Developing and Evaluating Complex Interventions.
- 40 ● This study will use comprehensive outcome measurements, including a series of
41 feasibility outcomes, which will support the refinement of a clinically feasible tai chi
42 protocol for a future full-scale RCT.
- 43 ● The sample size of this trial is relatively small and is not power based, which will
44

1 contribute to only a preliminary analysis of the effects of tai chi on the FSDSC.

2 **Introduction**

3 Breast cancer (BC) is regarded as the most common cancer among women worldwide
4 [1]. Although the number of BC survivors is increasing with improved cancer treatment, the
5 substantial negative effects associated with cancer and cancer treatments remain a significant
6 problem for survivors. Following the treatment of surgery, radiation therapy, antihormonal
7 therapy, and/or chemotherapy, BC patients can experience significant side effects, including
8 fatigue, sleep disturbance, and depression [2]. These frequently reported, troublesome
9 symptoms usually occur concurrently in BC patients as a symptom cluster [3, 4]. According
10 to Dodd et al. [5], a symptom cluster “consists of three or more symptoms that are related to
11 each other and that occur together” (p. 468). The fatigue-sleep disturbance-depression
12 symptom cluster (FSDSC) is one of the most frequent symptom clusters among BC patients,
13 which can negatively impact patients’ physical and psychosocial functioning status and
14 quality of life (QoL), including more severe cancer-related symptoms, lower treatment
15 compliance, poorer emotional conditions, worse financial hardship, and even shorter survival
16 time [6-8].

17 To date, no specific medications are available for the management of cancer symptom
18 clusters. Reviewing the previous evidence, various non-pharmacological approaches have
19 been used as a combination treatment with medication for the comprehensive management of
20 cancer-related symptoms [9-10]. However, most of the widely employed
21 non-pharmacological approaches, such as acupuncture [11], hypnotherapy [12], guided
22 imagery [13], massage [14], and electrical stimulation [15], require intensive professional
23 skills training, supervised practise, and specific equipment, all of which can be significantly
24 time- and energy-consuming and can considerably increase the consumption of healthcare
25 resources and costs. Moreover, due to fatigue intolerance, cancer patients are usually reluctant
26 to participate in energy-consuming non-pharmacological interventions such as intensive
27 exercise [16]. Thus, an energy-saving and cost-effective non-pharmacological approach
28 would be more appropriate for FSDSC management in cancer patients.

29 Traditional Chinese exercise (TCE) could be an appropriate and effective option for FSDSC
30 relief in BC patients given its low cost and mild-to-moderate intensity. Tai chi, a very popular
31 TCE, consists of several slow, simple, and repetitive body movements along with deep
32 breathing, and it is easy to master [17]. There has been increasing evidence of its positive
33 effects in targeting the management of individual symptoms such as fatigue, sleep disturbance,
34 and depression [18-20]. However, no clinical research has ever been performed using tai chi
35 exercise for symptom cluster management, especially the FSDSC in BC patients. The current
36 study therefore proposes to assess the feasibility and the preliminary effects of using an
37 evidence-based tai chi protocol for alleviating the FSDSC in BC patients through a pilot
38 randomized controlled trial (RCT).

39 **Methods and materials**

40 ***Study design***

41 The study’s design will be a two-parallel-arm, single-blinded (assessor) pilot RCT. The
42

1 participants will be randomly allocated into two groups: a tai chi intervention group and a
2 control group, with an allocation ratio of 1:1. The study period will be 12 weeks, which will
3 involve an 8-week tai chi intervention and a 4-week follow-up for the intervention group. A
4 CONSORT flowchart of the study is presented in **Figure 1**. The schedule of trial enrolment,
5 intervention data collection, and assessments are presented in **Table 1**. This protocol was
6 reported in accordance with the SPIRIT Checklist.

7 ***Study setting***

8 This study will be implemented in two tertiary medical centres in Mainland China, including
9 the Affiliated Hospital of Putian University (Fujian) and the Affiliated Hospital of Southwest
10 Medical University (Sichuan).

11 ***Sample size calculation***

12 Thirty or more participants per group is usually recommended as sufficient for a pilot study to
13 examine intervention feasibility [21] and to estimate a between-group effect for a subsequent
14 power analysis that can be used in the main study's sample size estimation [22]. Given that
15 the primary purpose of this study will be exploring the feasibility and acceptability of the
16 study's methodological procedures, intervention protocol, and questionnaires, 30 participants
17 per group was therefore determined to be an appropriate sample size. Taking into account a
18 conservative anticipation of a 20% dropout rate, the final sample size will therefore be 36 in
19 each group, with a total of 72 participants [23].

20 ***Inclusion and exclusion criteria***

21 Eligible participants will be recruited using the following inclusion criteria:

- 22 (1) adult female patients aged over 18 years;
- 23 (2) diagnosed with stage I, II, or IIIa BC (non-metastatic BC);
- 24 (3) have experienced at least a moderate level of fatigue, sleep disturbance, and depression,
25 with a score of greater than 3 (which means a score of "4" and above) on a 10-point scale,
26 from "0 (no symptom)" to "10 (worst symptom)" for each symptom in the past one
27 month;
- 28 (4) have completed breast cancer surgery for over one month;
- 29 (5) have recently (within the past two months) commenced adjuvant chemotherapy;
- 30 (6) able to speak and understand Mandarin Chinese; and
- 31 (7) willing and able to give written informed consent for study participation.

32 Potential participants will be excluded using the following exclusion criteria:

- 33 (1) presently taking medications for the treatment of fatigue, sleep disturbance, or depression,
34 such as antidepressant medications, psychostimulants, or hypnotics;
- 35 (2) extremely weak (unable to do physical activities due to advanced stages of chronic
36 illnesses) or have cognitive impairment and/or severe mental illness;
- 37 (3) have participated in a tai chi program during the previous six months;
- 38 (4) have practised other TCE for over 30 minutes, three times per week, during the previous
39 three months; and
- 40 (5) have scheduled other elective surgery within the trial period.

Recruitment

A research team will be formed before the commencement of the trial. Three investigators, including the doctoral investigator and two clinical nurses, will be primarily responsible for the subject recruitment and tai chi training. The investigators will receive intensive training from a qualified tai chi instructor to ensure a standardized tai chi practice. Prior to the tai chi intervention, the tai chi instructor will examine the accuracy of the movements among the three researchers, and the accuracy rate should be 100%. Two research assistants will conduct data collection and telephone follow-ups. To ensure the quality of data collection, the two research assistants will be trained on questionnaire data collection skills, including understanding the questionnaire items and standardizing their conversations with the participants. The academic supervisors of the doctoral investigator will monitor the entire study procedure on an ongoing basis through regular monthly meetings.

Among the hospitalized patients in the Breast Cancer Unit, potential participants will be recruited directly by the doctoral investigator and the two clinical nurses. Some potential participants who attend a breast cancer clinic for regular follow-ups will be referred by physicians and clinic nurses to the doctoral investigator and the two clinical nurses. A participant information sheet, including the research aim, the procedures, and the contact details of the study investigators, will be given to potential participants and will be explained by the doctoral investigator and the two clinical nurses. Potential participants who express interest in participating in the study will be screened for eligibility with reference to the inclusion and exclusion criteria by the doctoral investigator and the two clinical nurses. After their agreement to participate, the participants will be required to provide their written informed consent. The participants will be informed that they can withdraw from the study at any moment without any consequences.

Randomization and allocation concealment

The pilot trial will be randomized and controlled in a 1:1 allocation ratio. One set of randomization sequences will be generated via an online randomizer (<https://www.randomizer.org/>) based on the estimated sample size. To ensure allocation concealment, the randomization sequences will be generated by a statistician who will not be involved in any other parts of this study. Specifically, the statistician will use the online randomizer to generate the randomization sequences, which will include 36 even and 36 odd numbers. The randomization sequences will be accessed by the statistician only. Once an eligible participant consents to participate in the study and completes the baseline assessment, the two clinical nurses will telephone the statistician to determine which group the patient should be assigned to according to the pre-defined random numbers. The participants will be randomly assigned to either the tai chi intervention group or the control group.

Blinding

Due to the visible nature of the tai chi intervention, blinding of the study investigators and the participants will be impossible. Thus, blinding will only be applied to the outcome assessors (i.e., the two research assistants) in this pilot RCT to avoid potential detection bias during data collection. The two research assistants will be responsible for data collection and

1 telephone follow-ups, and they will not be involved in the subject recruitment process.

2 3 ***Tai chi intervention group***

4 In addition to the standard care provided to both the intervention group and the control group,
5 the participants in the intervention group will additionally receive instruction on easy 8 form
6 tai chi movements. The development and validation of the evidence-based tai chi protocol are
7 detailed in a methodological paper [24]. The intervention regime will last 60 minutes per
8 session, two sessions per week, for eight weeks, which is based on current research evidence,
9 practice standards/guidelines, theories, and experts' consensus [24]. To ensure that the
10 participants have fully mastered the tai chi skills, before the commencement of the
11 intervention, they will receive at least three 60-minute training sessions until they can perform
12 the movements correctly and smoothly, along with a home learning package in an
13 audio-visual format (i.e., a recorded video). The training will be conducted and led by either
14 the doctoral investigator or the two clinical nurses, and attendance will be recorded. All the
15 participants will be asked to perform the tai chi movements in front of the trainers (i.e., return
16 demonstration) to make sure that they are correctly performing each movement of the tai chi
17 exercise. In addition, the participants will be tested by the trainers during the last training
18 session to ensure that they have correctly performed the tai chi movements (via return
19 demonstration).

20 The intervention sessions will be 60 minutes and will be comprised of the following
21 components: a 10-minute warm-up, 25 to 30 minutes of easy 8 form tai chi practising, and a
22 10-minute cool-down. During each session, the participants will also have a 10-minute break
23 to rest. The tai chi intervention protocol was adapted in clinical practice to develop a
24 personalized intervention that will be tailored to the participants' convenience and preference
25 regarding the time and venue of the intervention. Details of the tai chi protocol are presented in
26 a methodological paper [24]. A specially designed exercise log will be provided to the
27 participants to record information related to their tai chi practice immediately after tai chi
28 practising each time, such as duration and frequency of practising tai chi, as well as any
29 potential adverse reactions related to tai chi, such as dizziness, knee pain, musculoskeletal
30 aches and pains, etc. The exercise logs will be returned to the research assistants on the date
31 of the participants' treatment or follow-up appointment at the hospital. To enhance the
32 participants' adherence to the tai chi intervention, the research assistants will conduct
33 telephone follow-ups every week to remind them to practise their tai chi and to collect
34 information on any potential adverse reactions related to the tai chi intervention.

35 ***Control group***

36 The participants allocated to the control group will receive a standard care package, which
37 will be a booklet on the self-management of cancer symptoms. This booklet will offer basic
38 knowledge and management strategies regarding FSDSC management in BC patients during
39 or after chemotherapy treatment. All the information listed in this booklet will be
40 comprehensively adapted from relevant national guidelines developed by professional
41 associations in cancer care and government health department websites, including the
42 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
43 (the NCCN Guidelines) [25] and the Department of Health – Government of Western

1 Australia [26]. Research evidence in published peer-reviewed articles will also be cited as
2 supporting information for the booklet's development [2, 27-29]. Additionally, the
3 participants will be asked to refrain from practising any exercises related to TCE during the
4 study, with reminders at all assessment time points. On completion of the pilot RCT, the
5 participants in the control group will have an opportunity to receive the tai chi training from
6 the study team.

7 ***Outcome measurements and follow-up***

8 The outcome measurements for this pilot RCT will include three categories, namely, baseline
9 assessments, feasibility and acceptability outcomes, and clinical outcomes. The feasibility and
10 acceptability outcomes will be the primary outcomes, while the clinical outcomes will be the
11 secondary outcomes. All the outcomes and follow-ups will be conducted by the two research
12 assistants.

13 ***Demographic and clinical characteristics of the participants***

14 A self-designed demographic and clinical data form will be employed to collect the
15 participants' socio-demographic data (e.g., age, education background, employment status,
16 marital status, and household income) and medical history (e.g., date of diagnosis, the current
17 stage of BC, and date and type of treatment) at baseline (T1).

18 ***Primary outcomes: Feasibility and acceptability***

19 **(1)** The feasibility assessment of subject recruitment and the follow-up process will include:
20 **(a)** the time that was taken to recruit the planned sample size of participants; **(b)** referral rate –
21 the number of referrals made by clinicians in different departments and hospitals divided by
22 all referrals; **(c)** recruitment rate – the number of subjects who enrolled in the study divided
23 by all subjects eligible for enrolment; **(d)** retention rate – the number of subjects who
24 completed the study divided by all subjects who enrolled in the study; **(e)** dropout rate – the
25 number of subjects who dropped out after randomization divided by all subjects who enrolled
26 in the study; and **(f)** feedback from the dropout subjects to identify their reasons for dropping
27 out. The feasibility of recruitment and follow-up process outcomes will be collected at
28 baseline (T1) and immediately after the intervention (T2).

29 **(2)** The feasibility assessment of the outcome measures will include the percentage of missing
30 values for each item of the scales used – the Brief Fatigue Inventory (BFI), the Pittsburgh
31 Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS), and the
32 Functional Assessment of Cancer Therapy-Breast (FACT-B) – at baseline (T1), immediately
33 after the intervention (T2), and four weeks after completion of the intervention (T3).

34 **(3)** The feasibility and acceptability of the intervention will include: **(a)** adherence rates – the
35 number of tai chi sessions practised divided by the total number of sessions required; **(b)** the
36 participants' feedback on and satisfaction with the intervention using a self-designed feedback
37 form; **(c)** records of adverse events associated with tai chi, which will be obtained from the
38 exercise logs; and **(d)** the number of participants who completed the exercise log. The
39 feasibility and acceptability of the intervention will be assessed immediately after the
40 intervention (T2).

Secondary outcomes: Fatigue, sleep disturbance, depression, and QoL

The fatigue, sleep disturbance, depression, and QoL of the BC patients as the secondary outcomes will be measured at T1, T2, and T3 using the BFI, the PSQI, the HADS, and the FACT-B.

(1) Fatigue: The participants' severity of fatigue and cancer-related fatigue in daily functioning will be measured using the BFI. The BFI has nine items, with higher scores corresponding to more severe fatigue [30, 31]. The Chinese version of the BFI has excellent internal consistency reliability (Cronbach's alpha from 0.90 to 0.92), as well as construct validity and convergent validity [32].

(2) Sleep disturbance: The participants' sleep quality and disturbance will be assessed using the PSQI. This questionnaire has seven domains: sleep latency, habitual sleep efficiency, subjective sleep quality, sleep duration, use of sleeping medication, sleep disturbance, and daytime dysfunction [33]. A total score will be calculated from the sum of the seven domains' scores. A higher total score indicates poorer sleep quality. The Chinese version of the PSQI has been demonstrated to be a reliable and valid scale, and it has been widely utilized among cancer patients [34].

(3) Depression: The HADS will be used to assess the participants' depression. The cut-off scores have been classified and labelled as 0 to 7 for "normal", 8 to 10 for "mild", 11 to 15 for "moderate", and ≥ 16 for "severe" [35]. As a reliable and valid tool for measuring depression, the HADS has been widely utilized among Chinese cancer patients, with well-documented psychometric properties [36].

(4) Quality of life: The FACT-B will be adopted to assess the participants' QoL. A higher score demonstrates better QoL. The FACT-B is available in a simplified Chinese version, with adequate psychometric properties reported among patients with BC [37].

Data management

The doctoral investigator and one of the research assistants will enter all the collected data into a computer with a double data entry approach. To ensure that there are no discrepancies or coding errors after running descriptive and inferential statistics, data cleaning will be conducted before data analysis [38]. First, the datasets will be checked against the paper recordings of raw data to ensure that the data coding is correct. Then, double-checking will be undertaken by the other research assistant to ensure accuracy. All electronic data will be retained in a compressed folder using password-protected access systems, and all hard copies of the materials will be retained in a cabinet at the study sites. Storage and disposal of research data hard copies will strictly follow the regulations and policies of the lead investigator's institution and the study sites, including the Charles Darwin University Research Data Management Guide.

Data analysis

Statistical analyses will be conducted using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA). The intention-to-treat (ITT) principle will be utilized for

1 the management of missing data. Effect sizes (ES) of between-group comparisons will be
2 estimated using Cohen's *d* [39]. The chi-squared test or Fisher's exact test will be used to
3 examine the comparisons between the control and intervention groups for categorical
4 variables (e.g., education background, referral rate, retention rate, etc.). An independent t-test
5 or the Mann-Whitney U test will be utilized for the continuous variables (e.g., age, household
6 income, etc.). The Generalized Estimating Equation (GEE) model will be performed for
7 repeated multivariate analysis between the two study groups for the total scores and domain
8 scores of the BFI, the PSQI, the HADS, and the FACT-B. The significance level to identify
9 statistical differences will be $p < 0.05$.

10 **Patient and public involvement**

11 No patient was involved in the study design or any other part of this protocol.

12 **Ethics and dissemination**

13 This study was registered at ClinicalTrials.gov (identifier NCT04190342) before its
14 commencement. The study has been approved by the Human Research Ethics Committee at
15 Charles Darwin University (H19094), the Clinical Trial Ethics Committee at the Affiliated
16 Hospital of Southwest Medical University (KY2019133), and the Clinical Trial Ethics
17 Committee at the Affiliated Hospital of Putian University (201932). The abstract of this study
18 has been submitted to Sigma's 32nd International Nursing Research Congress for presentation
19 in 2021. The results of the trial will be published in peer-reviewed scientific journals.

20 **Discussion**

21 As one of the most common symptom clusters in BC patients, the FSDSC can significantly
22 deteriorate patients' QoL and daily functioning [40, 41]. An increasing number of studies
23 have demonstrated that tai chi has beneficial effects on symptom management in cancer
24 patients; however, almost all the studies focused on individual symptoms only, such as fatigue,
25 sleep disturbance, or depression [42-44]. No study has ever been performed to investigate the
26 role of tai chi in managing symptom clusters in the BC population. This highlights a great
27 need to explore the effects of tai chi on the FSDSC in BC patients. Given that the patients will
28 have already experienced fatigue upon enrolment in this pilot RCT, lengthy and complicated
29 tai chi movements will be avoided. Easy 8 form tai chi, a traditional Chinese mind-body
30 exercise with only eight simple movements, is an appropriate intervention for FSDSC
31 management as it is easy to learn, is less energy-consuming, and requires no specific
32 equipment [45, 46].

33 This study has some strengths. According to the Medical Research Council Framework for
34 Developing and Evaluating Complex Interventions, the feasibility and acceptability of a
35 proposed intervention and research methodological procedures should be fully examined prior
36 to performing the full-scale study [47]. In this current pilot RCT, the feasibility and
37 acceptability of an easy 8 form tai chi intervention program will be assessed comprehensively
38 using a series of feasibility outcomes, including subject recruitment, intervention delivery,
39 and outcome assessments. A comprehensive assessment will promote the refinement of the
40 intervention protocol for the future main study. Furthermore, different from some current
41 non-pharmacological studies, the tai chi intervention protocol used in the current pilot RCT

1 will be evidence-based and rigorously developed based on systematic review evidence and
2 recommendations [48-56]; TCE principles, theories [57, 58], and practice standards [46, 59];
3 the characteristics of cancer-related symptoms; and the consensus of an expert panel. In
4 addition, an FSDSC self-management education booklet will be designed and provided to the
5 participants in both the intervention and control groups. The information listed in this booklet
6 will be comprehensively adapted from relevant national guidelines, professional bodies, and
7 research evidence in published peer-reviewed articles. The self-management education
8 booklet will be used as an enhanced care component to improve the patients' knowledge and
9 relevant coping strategies for FSDSC management. Finally, a safety assessment of the tai chi
10 protocol for cancer patients will be set as one of the feasibility outcomes, which has rarely
11 been measured in existing tai chi interventional studies. Although tai chi is a non-invasive
12 intervention that is generally regarded as a relatively safe approach, the exercise program
13 might still contribute to some minor adverse events such as a lumbar sprain, musculoskeletal
14 aches and pains, dizziness, knee pain, etc. [60]. Therefore, any potential adverse events
15 related to practising tai chi will be monitored and reported in the exercise log.

16 This study also has some limitations. Given the limited study sites, the study sample in this
17 study may not offer a completely representative sample of BC patients who are experiencing
18 the FSDSC. Due to the visible nature of the tai chi intervention, the blinding of the
19 participants and the tai chi instructor cannot be performed in this study, which might increase
20 the risk of detection bias during the study's implementation, although the outcome assessors
21 will be blinded to the intervention allocation. The lack of long-term follow-up to assess the
22 ongoing effects of tai chi might be another limitation, but this can be considered in the future
23 full-scale RCT as one of the main study outcomes.

24
25 This study will utilize a rigorously designed RCT to assess the feasibility and preliminary
26 effects of an evidence-based tai chi program for alleviating the FSDSC in BC patients. The
27 convenience of the tai chi for the self-management of the FSDSC may provide BC patients,
28 healthcare professionals, and policymakers with further guidance in FSDSC management in
29 the long run. Furthermore, the results of this trial will contribute to a future multi-centre
30 large-scale main RCT to further conclude the research evidence on the effects and safety of
31 tai chi for FSDSC management in BC patients.

32 **Trial status**

33 The study began in May 2020. Data collection and analysis is ongoing.

34 **Funding**

35 This trial was funded by the Australian Government Research Training Program (RTP)
36 scholarship, and the Award/Grant number is not applicable.

37 **Conflict of interest**

38 No conflict of interest regarding the publication of this paper was declared.

39 **Authors' contributions**

40 **Yao LQ:** study conception and design, trial organization, administration and coordination,
41 quality assurance, and manuscript drafting and revision; **Tan JY:** study conception and design,

1 study procedure supervision, and manuscript revision; **Turner C**: study conception and
2 design, study procedure supervision, and manuscript revision; **Wang T**: study design, study
3 procedure supervision, and manuscript revision.

For peer review only

Table 1. The schedule of trial enrolment, interventions, and assessments

	Study Period				
	Before Enrolment (0 weeks)	Intervention Period (1-8 weeks)	End of Intervention (8 weeks)	Follow-up Period (9-12 weeks)	End of Follow-up (12 weeks)
Inclusion/exclusion criteria	×				
Informed consent	×				
Demographic characteristics	×				
Randomization and allocation	×				
Feasibility of recruitment and follow-up process	×		×	×	×
Feasibility assessment of the outcome measures	×		×		×
Feasibility and acceptability of the intervention		×			
BFI	×		×		×
HADS	×		×		×
PSQI	×		×		×
FACT-B	×		×		×
Safety measurement		×			

References

- [1] Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol*. 2019 May 1;30(5):781-87. doi: 10.1093/annonc/mdz051
- [2] Jain S, Boyd C, Fiorentino L, Khorsan R, Crawford C. Are there efficacious treatments for treating the fatigue-sleep disturbance-depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL(©)). *Breast Cancer (Dove Med Press)*. 2015 Sep 2;7:267-91. doi: 10.2147/BCTT.S25014
- [3] Hsu HT, Lin KC, Wu LM, Juan CH, Hou MF, Hwang SL, Liu Y, Dodd MJ. Symptom cluster trajectories during chemotherapy in breast cancer outpatients. *J Pain Symptom Manage*. 2017 Jun;53(6):1017-25. doi: 10.1016/j.jpainsymman.2016.12.354
- [4] Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. *Sleep*. 2012 Feb 1;35(2):237-45. doi: 10.5665/sleep.1630
- [5] Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum*. 2001 Apr;28(3):465-70.
- [6] Aktas A, Kirkova J, Walsh D, Karafa M, Nair A, Schleckman E. The psychometric properties of cancer multi-symptom assessment instruments: a comprehensive review. *J Pain Symptom Manage*. 2012;43(2):334-5.
- [7] Ho SY, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. *J Pain Symptom Manage*. 2015 Apr;49(4):707-15. doi: 10.1016/j.jpainsymman.2014.09.009
- [8] Kim HJ, Barsevick AM, Beck SL, Dudley W. Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer: a secondary analysis. *Oncol Nurs Forum*. 2012 Jan;39(1):E20-30. doi: 10.1188/12.ONF.E20-E30
- [9] Hökkä M, Kaakinen P, Pölkki T. A systematic review: non-pharmacological interventions in treating pain in patients with advanced cancer. *J Adv Nurs*. 2014 Sep;70(9):1954-69. doi: 10.1111/jan.12424
- [10] Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: a systematic review of non-pharmacological interventions. *Int J Nurs Pract*. 2014 Oct;20(5):549-60. doi: 10.1111/ijn.12211
- [11] Yin C, Buchheit TE, Park JJ. Acupuncture for chronic pain: an update and critical overview. *Curr Opin Anaesthesiol*. 2017 Oct;30(5):583-92. doi: 10.1097/ACO.0000000000000501
- [12] McKernan LC, Finn MTM, Patterson DR, Williams RM, Jensen MP. Clinical hypnosis for chronic pain in outpatient integrative medicine: an implementation and training model. *J Altern Complement Med*. 2020 Feb;26(2):107-12. doi: 10.1089/acm.2019.0259
- [13] Charalambous A, Giannakopoulou M, Bozas E, Marcou Y, Kitsios P, Paikousis L. Guided imagery and progressive muscle relaxation as a cluster of symptoms management intervention in patients receiving chemotherapy: a randomized control trial. *PLoS One*. 2016 Jun 24;11(6):e0156911. doi: 10.1371/journal.pone.0156911

- [14] Lopez G, Liu W, Milbury K, Spelman A, Wei Q, Bruera E, Cohen L. The effects of oncology massage on symptom self-report for cancer patients and their caregivers. *Support Care Cancer*. 2017 Dec;25(12):3645-50. doi: 10.1007/s00520-017-3784-7
- [15] Nguyen LT, Yates P, Annoussamy LC, Truong TQ. The effectiveness of non-pharmacological interventions in the management of symptom clusters in adult cancer patients: a systematic review protocol. *JBISIRIR-2016-2476*. 2016 Apr;14(4):49-59. doi: 10.11124/JBISIRIR-2016-2476
- [16] Zou L, Wang H, Xiao Z, Fang Q, Zhang M, Li T, Du G, Liu Y. Tai chi for health benefits in patients with multiple sclerosis: a systematic review. *PLoS One*. 2017 Feb 9;12(2):e0170212. doi: 10.1371/journal.pone.0170212
- [17] Jahnke R, Larkey L, Rogers C, Etnier J, Lin F. A comprehensive review of health benefits of qigong and tai chi. *Am J Health Promot*. 2010 Jul-Aug;24(6):e1-e25. doi: 10.4278/ajhp.081013-LIT-248
- [18] Irwin MR, Olmstead R, Carrillo C, Sadeghi N, Nicassio P, Ganz PA, Bower JE. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. *J Clin Oncol*. 2017 Aug 10;35(23):2656-65. doi: 10.1200/JCO.2016.71.0285. Epub 2017 May 10. Erratum in: *J Clin Oncol*. 2017 Dec 20;35(36):4096.
- [19] McQuade JL, Prinsloo S, Chang DZ, Spelman A, Wei Q, Basen-Engquist K, Harrison C, Zhang Z, Kuban D, Lee A, Cohen L. Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial. *Psychooncology*. 2017 Nov;26(11):1936-43. doi: 10.1002/pon.4256
- [20] Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai chi exercise for cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial. *J Pain Symptom Manage*. 2016 Mar;51(3):504-11. doi: 10.1016/j.jpainsymman.2015.11.020
- [21] Browne RH. On the use of a pilot sample for sample size determination. *Stat Med*. 1995;14(17):1933-40.
- [22] Hertzog MA. Considerations in determining sample size for pilot studies. *Res Nurs Health*. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247
- [23] Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY. Feasibility and acceptability of a tai chi chih randomized controlled trial in senior female cancer survivors. *Integr Cancer Ther*. 2013 Nov;12(6):464-74. doi: 10.1177/1534735413485418
- [24] Yao LQ, Tan JY, Turner C, Wang T. Development and validation of a tai chi intervention protocol for managing the fatigue-sleep disturbance-depression symptom cluster in female breast cancer patients. *Complement Ther Med* (in press).
- [25] NCCN Cancer-Related Fatigue Panel (2018). National Comprehensive Cancer Network Clinical practice guidelines in oncology. Cancer-Related Fatigue, version 2.
- [26] Department of Health at the Government of Western Australia. Retrieved from <https://www.health.gov.au/resources>.

- [27] Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C; National Comprehensive Cancer Network. Cancer-related fatigue, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122
- [28] Berger AM, Mitchell SA, Jacobsen PB, Pirl WF. Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? *CA Cancer J Clin*. 2015 May-Jun;65(3):190-211. doi: 10.3322/caac.21268
- [29] Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. *J Clin Oncol*. 2012 Apr 10;30(11):1187-96. doi: 10.1200/JCO.2011.39.7372
- [30] Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. *Cancer*. 1999 Mar 1;85(5):1186-96. doi: 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cnrcr24>3.0.co;2-n
- [31] Nunes AF, Bezerra CO, Custódio JDS, Friedrich CF, Oliveira IS, Lunardi AC. Clinimetric properties of the brief fatigue inventory applied to oncological patients hospitalized for chemotherapy. *J Pain Symptom Manage*. 2019 Feb;57(2):297-303. doi: 10.1016/j.jpainsymman.2018.10.508
- [32] Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS. Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). *J Pain Symptom Manage*. 2004 Apr;27(4):322-32. doi: 10.1016/j.jpainsymman.2003.09.008
- [33] Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4
- [34] Tsai PS, Wang SY, Wang MY, Su CT, Yang TT, Huang CJ, Fang SC. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. *Qual Life Res*. 2005 Oct;14(8):1943-52. doi: 10.1007/s11136-005-4346-x
- [35] Smith RP, Zigmond AS. *The Hospital Anxiety and Depression Scale Manual*. Windsor: NFER—Nelson, 1994.
- [36] Wang W, Chair SY, Thompson DR, Twinn SF. A psychometric evaluation of the Chinese version of the Hospital Anxiety and Depression Scale in patients with coronary heart disease. *J Clin Nurs*. 2009 Jul;18(13):1908-15. doi: 10.1111/j.1365-2702.2008.02736.x
- [37] Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast cancer. *Breast Cancer Res Treat*. 2007 Dec;106(3):413-18. doi: 10.1007/s10549-007-9511-1
- [38] Portney LG, Watkins MP. *Foundations of Clinical Research: Applications to Practice (Vol. 892)*. Upper Saddle River, NJ: Pearson/Prentice Hall, 2009.

- [39] Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
- [40] Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G. The relationship between depression and physical symptom burden in advanced cancer. *BMJ Support Palliat Care*. 2015 Dec;5(4):381-8. doi: 10.1136/bmjspcare-2012-000380
- [41] Oh H, Seo Y, Jeong H, Seo W. The identification of multiple symptom clusters and their effects on functional performance in cancer patients. *J Clin Nurs*. 2012 Oct;21(19-20):2832-42. doi: 10.1111/j.1365-2702.2011.04057.x
- [42] Qiang WM, Dong FQ, Yan L, et al. Comparison of two different exercise programs in breast cancer patients after postoperative adjuvant chemotherapy. *Chin J Nurs*. 2011;46:537e540.
- [43] Jiang MY. Influence of shadowboxing on improving cancer-related fatigue and sleeping quality of patients with advanced lung cancer. *Chin Nurs Res*. 2013;27:420e421.
- [44] Larkey LK, Roe DJ, Weihs KL, Jahnke R, Lopez AM, Rogers CE, Oh B, Guillen-Rodriguez J. Randomized controlled trial of qigong/tai chi easy on cancer-related fatigue in breast cancer survivors. *Ann Behav Med*. 2015 Apr;49(2):165-76. doi: 10.1007/s12160-014-9645-4. PMID: 25124456; PMCID: PMC4329282.
- [45] Tadros G, Ormerod S, Dobson-Smyth P, Gallon M, Doherty D, Carryer A, Oyeboode J, Kingston P. The management of behavioural and psychological symptoms of dementia in residential homes: does tai chi have any role for people with dementia? *Dementia (London)*. 2013 Mar;12(2):268-79. doi: 10.1177/1471301211422769
- [46] Li F, Fisher KJ, Harmer P, Shirai M. A simpler eight-form easy tai chi for elderly adults. *J Aging Phys Act*. 2003;11(2):206-18.
- [47] Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ*. 2008 Sep 29;337:a1655. doi: 10.1136/bmj.a1655
- [48] Ma HL, Tan JY, Yang LH, Tao L, Liao QJ. Current evidence on traditional Chinese exercises for cancer-related fatigue: a quantitative synthesis of randomized controlled trials. *Eur J Integr Med*. 2016;8(5):707-14. doi:10.1016/j.eujim.2016.05.007
- [49] Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, Song R. Tai chi and qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. *J Cancer Surviv*. 2018 Apr;12(2):256-67. doi: 10.1007/s11764-017-0665-5
- [50] Song S, Yu J, Ruan Y, Liu X, Xiu L, Yue X. Ameliorative effects of tai chi on cancer-related fatigue: a meta-analysis of randomized controlled trials. *Support Care Cancer*. 2018 Jul;26(7):2091-102. doi: 10.1007/s00520-018-4136-y
- [51] Van Vu D, Molassiotis A, Ching SSY, Le TT. Effects of Qigong on symptom management in cancer patients: a systematic review. *Complement Ther Clin Pract*. 2017 Nov;29:111-21. doi: 10.1016/j.ctcp.2017.09.005
- [52] Xiang Y, Lu L, Chen X, Wen Z. Does tai chi relieve fatigue? A systematic review and meta-analysis of randomized controlled trials. *PLoS One*. 2017 Apr 5;12(4):e0174872. doi:

1
2
3
4
10.1371/journal.pone.0174872

5 [53] Yao LQ, Tan JY, Turner C, Wang T, Liu XL. Traditional Chinese exercise for cancer-related
6 sleep disturbance: a systematic review and descriptive analysis of randomized clinical trials.
7 Complement Ther Clin Pract. doi:10.1016/j.ctcp.2020.101197

8 [54] Zeng Y, Xie X, Cheng ASK. Qigong or tai chi in cancer care: an updated systematic review
9 and meta-analysis. Curr Oncol Rep. 2019 Apr 6;21(6):48. doi: 10.1007/s11912-019-0786-2

10 [55] Ni X, Chan RJ, Yates P, Hu W, Huang X, Lou Y. The effects of tai chi on quality of life of
11 cancer survivors: a systematic review and meta-analysis. Support Care Cancer. 2019
12 Oct;27(10):3701-16. doi: 10.1007/s00520-019-04911-0

13 [56] Hilfiker R, Meichtry A, Eicher M, Nilsson Balfe L, Knols RH, Verra ML, Taeymans J.
14 Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during
15 or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis.
16 Br J Sports Med. 2018 May;52(10):651-8. doi: 10.1136/bjsports-2016-096422

17 [57] Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: a
18 descriptive review. Brain Behav Immun. 2016 Jan;51:1-11. doi: 10.1016/j.bbi.2015.06.012

19 [58] Larkey L, Jahnke R, Etnier J, Gonzalez J. Meditative movement as a category of exercise:
20 implications for research. J Phys Act Health. 2009 Mar;6(2):230-8. doi: 10.1123/jpah.6.2.230

21 [59] Committee of Chinese Sports College Textbook. Chinese Wushu Textbook (Part I). People's
22 Sports Publishing House of China: Beijing, 2003.

23 [60] Jia X, Jiang C, Tao J, Li Y, Zhou Y, Chen LD. Effects of core strength training combined
24 with tai chi chuan for the musculoskeletal system and cardiopulmonary function in older adults: a
25 study protocol for a randomized controlled trial. Medicine (Baltimore). 2018 Aug;97(35):e12024.
26 doi: 10.1097/MD.00000000000012024
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. A CONSORT flowchart of the study



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>Page 1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>Page 2</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>Not applicable</u>
Protocol version	3	Date and version identifier	<u>Page 2</u>
Funding	4	Sources and types of financial, material, and other support	<u>Page 10</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>Page 11</u>
	5b	Name and contact information for the trial sponsor	<u>Page 1</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>Page 11</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>Page 8</u>

1 Introduction

2			
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention
5			
6		6b	Explanation for choice of comparators
7			
8	Objectives	7	Specific objectives or hypotheses
9			
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
12			
13			
14	Methods: Participants, interventions, and outcomes		
15			
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
17			be collected. Reference to where list of study sites can be obtained
18			
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)
21			
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be
23			administered
24			
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
26			change in response to harms, participant request, or improving/worsening disease)
27			
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
29			(eg, drug tablet return, laboratory tests)
30			
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
32			
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation
35			(eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
36			efficacy and harm outcomes is strongly recommended
37			
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits
39			for participants. A schematic diagram is highly recommended (see Figure)
40			
41			
42			
43			
44			
45			
46			

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>Page 4</u>
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>Page 4-5</u>
5				
6	Methods: Assignment of interventions (for controlled trials)			
7	Allocation:			
8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>Page 5</u>
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>Page 5</u>
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>Page 5</u>
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>Page 5</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>Page 5</u>
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>Page 7-8</u>
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>Page 8</u>
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>Page 8</u>
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>Page 8-9</u>
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>Page 8-9</u>
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>Page 8-9</u>
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>Page 8</u>
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>Page 8</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>Page 7</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>Page 5</u>
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>Page 9</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>Not applicable</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>Page 4 & 5</u>
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>Not applicable</u>
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>Page 8</u>
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>Page 10</u>
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>Page 8</u>
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>Not applicable</u>
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>Page 9</u>
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>Not applicable</u>
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>Not applicable</u>
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>Supplementary file</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>Not applicable</u>
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40
 41
 42
 43
 44
 45
 46

BMJ Open

Feasibility and potential effects of tai chi for the fatigue-sleep disturbance-depression symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048115.R2
Article Type:	Protocol
Date Submitted by the Author:	03-Aug-2021
Complete List of Authors:	Yao, Li-Qun; Charles Darwin University, College of Nursing and Midwifery Brisbane Centre Tan, Jing-Yu (Benjamin); Charles Darwin University, College of Nursing and Midwifery Brisbane Centre Turner, Catherine; Charles Darwin University, College of Nursing and Midwifery Brisbane centre Wang, Tao ; Charles Darwin University, College of Nursing and Midwifery Brisbane Centre
Primary Subject Heading:	Complementary medicine
Secondary Subject Heading:	Nursing, Oncology
Keywords:	Breast tumours < ONCOLOGY, COMPLEMENTARY MEDICINE, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 **Title Page**
5

6 2 Feasibility and potential effects of tai chi for the fatigue-sleep disturbance-depression
7 3 symptom cluster in breast cancer patients: Protocol of a preliminary randomized controlled
8 4 trial
9
10
11

12 6 **Li-Qun Yao** PhD liqun.yao@students.cdu.edu.au

13 7 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
14 8 410 Ann Street, Brisbane, QLD 4000, Australia
15
16
17

18 9 **Jing-Yu (Benjamin) Tan** PhD RN benjamin.tan@cdu.edu.au

19 10 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
20 11 410 Ann Street, Brisbane, QLD 4000, Australia
21
22

23 12 **Catherine Turner** AM PhD RN catherine.turner@cdu.edu.au

24 13 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
25 14 410 Ann Street, Brisbane, QLD 4000, Australia
26
27
28

29 15 **Tao Wang** PhD alison.wang@cdu.edu.au

30 16 Charles Darwin University, College of Nursing and Midwifery Brisbane Centre, Level 11,
31 17 410 Ann Street, Brisbane, QLD 4000, Australia
32
33
34

35 19 Correspondence

36 20 **Associate Professor Jing-Yu (Benjamin) Tan** PhD RN

37 21 Associate Professor in Nursing & Associate Dean Research

38 22 College of Nursing and Midwifery Brisbane Centre

39 23 Charles Darwin University

40 24 Level 11, 410 Ann Street, Brisbane, QLD 4000, Australia

41 25 Email: benjamin.tan@cdu.edu.au; Tel (Office): +61 7 3169 4269
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Abstract

2 **Introduction** The fatigue-sleep disturbance-depression symptom cluster (FSDSC) is one of
3 the most common and debilitating side effects in breast cancer (BC) patients throughout their
4 treatment trajectory. Tai chi has been supported as a promising non-pharmacological
5 intervention for the individual symptom relief of cancer-related fatigue, sleep disturbance, and
6 depression. However, relevant evidence of using tai chi for FSDSC management in BC
7 patients has been lacking.

8
9 **Methods** This study will be a two-arm, single-blinded pilot randomized controlled trial (RCT)
10 involving an 8-week intervention and a 4-week follow-up. Seventy-two BC patients
11 experiencing the FSDSC will be recruited from two tertiary medical centres in China. The
12 participants will be randomized to either a tai chi group (n=36) or a control group (n=36). The
13 participants in the tai chi group will receive an 8-week tai chi intervention in addition to
14 standard care, while the participants in the control group will receive standard care only
15 consisting of a booklet on the self-management of cancer symptoms. The primary outcomes
16 will include a series of feasibility assessments of the study protocol in relation to the study's
17 methodological procedures, including subject recruitment and follow-up process, completion
18 of study questionnaires, and the feasibility, acceptability, and safety of the intervention. The
19 secondary outcomes will be the clinical outcomes regarding the effects of tai chi on the
20 FSDSC and quality of life, which will be evaluated by the Brief Fatigue Inventory (BFI), the
21 Pittsburgh Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS),
22 and the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaires.

23
24 **Ethics and dissemination** Ethics approval was obtained from relevant sites (H19094,
25 KY2019133, 201932). The findings of the study will be published in peer-reviewed scientific
26 journals and at conferences.

27
28 **Trail registration:** ClinicalTrials.gov, identifier NCT04190342. Registered on 3 December
29 2019.

30
31 **Keywords:** Breast cancer; Fatigue; Sleep disturbance; Depression; Symptom cluster; Tai chi

32 **Strengths and limitations of this study**

- 33 ● This will be the first clinical study to explore the feasibility and preliminary effects of tai
34 chi on FSDSC management in BC patients.
- 35 ● This study will use an evidence-based tai chi protocol in the intervention group which
36 was comprehensively developed based on best available research evidence, guidelines,
37 theories, and practice standards.
- 38 ● The design of the pilot study will be guided by the Medical Research Council
39 Framework for Developing and Evaluating Complex Interventions.
- 40 ● This study will use comprehensive outcome measurements, including a series of
41 feasibility outcomes, which will support the refinement of a clinically feasible tai chi
42 protocol for a future full-scale RCT.
- 43 ● The sample size of this trial is relatively small and is not power based, which will
44

1 contribute to only a preliminary analysis of the effects of tai chi on the FSDSC.

2 **Introduction**

3 Breast cancer (BC) is regarded as the most common cancer among women worldwide
4 [1]. Although the number of BC survivors is increasing with improved cancer treatment, the
5 substantial negative effects associated with cancer and cancer treatments remain a significant
6 problem for survivors. Following the treatment of surgery, radiation therapy, antihormonal
7 therapy, and/or chemotherapy, BC patients can experience significant side effects, including
8 fatigue, sleep disturbance, and depression [2]. These frequently reported, troublesome
9 symptoms usually occur concurrently in BC patients as a symptom cluster [3, 4]. According
10 to Dodd et al. [5], a symptom cluster “consists of three or more symptoms that are related to
11 each other and that occur together” (p. 468). The fatigue-sleep disturbance-depression
12 symptom cluster (FSDSC) is one of the most frequent symptom clusters among BC patients,
13 which can negatively impact patients’ physical and psychosocial functioning status and
14 quality of life (QoL), including more severe cancer-related symptoms, lower treatment
15 compliance, poorer emotional conditions, worse financial hardship, and even shorter survival
16 time [6-8].

17 To date, no specific medications are available for the management of cancer symptom
18 clusters. Reviewing the previous evidence, various non-pharmacological approaches have
19 been used as a combination treatment with medication for the comprehensive management of
20 cancer-related symptoms [9-10]. However, most of the widely employed
21 non-pharmacological approaches, such as acupuncture [11], hypnotherapy [12], guided
22 imagery [13], massage [14], and electrical stimulation [15], require intensive professional
23 skills training, supervised practise, and specific equipment, all of which can be significantly
24 time- and energy-consuming and can considerably increase the consumption of healthcare
25 resources and costs. Moreover, due to fatigue intolerance, cancer patients are usually reluctant
26 to participate in energy-consuming non-pharmacological interventions such as intensive
27 exercise [16]. Thus, an energy-saving and cost-effective non-pharmacological approach
28 would be more appropriate for FSDSC management in cancer patients.

29 Traditional Chinese exercise (TCE) could be an appropriate and effective option for FSDSC
30 relief in BC patients given its low cost and mild-to-moderate intensity. Tai chi, a very popular
31 TCE, consists of several slow, simple, and repetitive body movements along with deep
32 breathing, and it is easy to master [17]. There has been increasing evidence of its positive
33 effects in targeting the management of individual symptoms such as fatigue, sleep disturbance,
34 and depression [18-20]. However, no clinical research has ever been performed using tai chi
35 exercise for symptom cluster management, especially the FSDSC in BC patients. The current
36 study therefore proposes to assess the feasibility and the preliminary effects of using an
37 evidence-based tai chi protocol for alleviating the FSDSC in BC patients through a pilot
38 randomized controlled trial (RCT).

39 **Methods and materials**

40 ***Study design***

41 The study’s design will be a two-parallel-arm, single-blinded (assessor) pilot RCT. The
42

1 participants will be randomly allocated into two groups: a tai chi intervention group and a
2 control group, with an allocation ratio of 1:1. The study period will be 12 weeks, which will
3 involve an 8-week tai chi intervention and a 4-week follow-up for the intervention group. A
4 CONSORT flowchart of the study is presented in **Figure 1**. The schedule of trial enrolment,
5 intervention data collection, and assessments are presented in **Table 1**. This protocol was
6 reported in accordance with the SPIRIT Checklist.

8 ***Study setting***

9 This study will be implemented in two tertiary medical centres in Mainland China, including
10 the Affiliated Hospital of Putian University (Fujian) and the Affiliated Hospital of Southwest
11 Medical University (Sichuan).

13 ***Sample size calculation***

14 Thirty or more participants per group is usually recommended as sufficient for a pilot study to
15 examine intervention feasibility [21] and to estimate a between-group effect for a subsequent
16 power analysis that can be used in the main study's sample size estimation [22]. Given that
17 the primary purpose of this study will be exploring the feasibility and acceptability of the
18 study's methodological procedures, intervention protocol, and questionnaires, 30 participants
19 per group was therefore determined to be an appropriate sample size. Taking into account a
20 conservative anticipation of a 20% dropout rate, the final sample size will therefore be 36 in
21 each group, with a total of 72 participants [23].

23 ***Inclusion and exclusion criteria***

24 Eligible participants will be recruited using the following inclusion criteria:

- 25 (1) adult female patients aged over 18 years;
- 26 (2) diagnosed with stage I, II, or IIIa BC (non-metastatic BC);
- 27 (3) have experienced at least a moderate level of fatigue, sleep disturbance, and depression,
28 with a score of greater than 3 (which means a score of "4" and above) on a 10-point scale,
29 from "0 (no symptom)" to "10 (worst symptom)" for each symptom in the past one
30 month;
- 31 (4) have completed breast cancer surgery for over one month;
- 32 (5) have recently (within the past two months) commenced adjuvant chemotherapy;
- 33 (6) able to speak and understand Mandarin Chinese; and
- 34 (7) willing and able to give written informed consent for study participation.

35 Potential participants will be excluded using the following exclusion criteria:

- 36 (1) presently taking medications for the treatment of fatigue, sleep disturbance, or depression,
37 such as antidepressant medications, psychostimulants, or hypnotics;
- 38 (2) extremely weak (unable to do physical activities due to advanced stages of chronic
39 illnesses) or have cognitive impairment and/or severe mental illness;
- 40 (3) have participated in a tai chi program during the previous six months;
- 41 (4) have practised other TCE for over 30 minutes, three times per week, during the previous
42 three months; and
- 43 (5) have scheduled other elective surgery within the trial period.

Recruitment

A research team will be formed before the commencement of the trial. Three investigators, including the doctoral investigator and two clinical nurses, will be primarily responsible for the subject recruitment and tai chi training. The investigators will receive intensive training from a qualified tai chi instructor to ensure a standardized tai chi practice. Prior to the tai chi intervention, the tai chi instructor will examine the accuracy of the movements among the three researchers, and the accuracy rate should be 100%. Two research assistants will conduct data collection and telephone follow-ups. To ensure the quality of data collection, the two research assistants will be trained on questionnaire data collection skills, including understanding the questionnaire items and standardizing their conversations with the participants. The academic supervisors of the doctoral investigator will monitor the entire study procedure on an ongoing basis through regular monthly meetings.

Among the hospitalized patients in the Breast Cancer Unit, potential participants will be recruited directly by the doctoral investigator and the two clinical nurses. Some potential participants who attend a breast cancer clinic for regular follow-ups will be referred by physicians and clinic nurses to the doctoral investigator and the two clinical nurses. A participant information sheet, including the research aim, the procedures, and the contact details of the study investigators, will be given to potential participants and will be explained by the doctoral investigator and the two clinical nurses. Potential participants who express interest in participating in the study will be screened for eligibility with reference to the inclusion and exclusion criteria by the doctoral investigator and the two clinical nurses. After their agreement to participate, the participants will be required to provide their written informed consent. The participants will be informed that they can withdraw from the study at any moment without any consequences.

Randomization and allocation concealment

The pilot trial will be randomized and controlled in a 1:1 allocation ratio. One set of randomization sequences will be generated via an online randomizer (<https://www.randomizer.org/>) based on the estimated sample size. To ensure allocation concealment, the randomization sequences will be generated by a statistician who will not be involved in any other parts of this study. Specifically, the statistician will use the online randomizer to generate the randomization sequences, which will include 36 even and 36 odd numbers. The randomization sequences will be accessed by the statistician only. Once an eligible participant consents to participate in the study and completes the baseline assessment, the two clinical nurses will telephone the statistician to determine which group the patient should be assigned to according to the pre-defined random numbers. The participants will be randomly assigned to either the tai chi intervention group or the control group.

Blinding

Due to the visible nature of the tai chi intervention, blinding of the study investigators and the participants will be impossible. Thus, blinding will only be applied to the outcome assessors (i.e., the two research assistants) in this pilot RCT to avoid potential detection bias during data collection. The two research assistants will be responsible for data collection and

1 telephone follow-ups, and they will not be involved in the subject recruitment process.

2 3 ***Tai chi intervention group***

4 In addition to the standard care provided to both the intervention group and the control group,
5 the participants in the intervention group will additionally receive instruction on easy 8 form
6 tai chi movements. The development and validation of the evidence-based tai chi protocol are
7 detailed in a methodological paper [24]. The intervention regime will last 60 minutes per
8 session, two sessions per week, for eight weeks, which is based on current research evidence,
9 practice standards/guidelines, theories, and experts' consensus [24]. To ensure that the
10 participants have fully mastered the tai chi skills, before the commencement of the
11 intervention, they will receive at least three 60-minute training sessions until they can perform
12 the movements correctly and smoothly, along with a home learning package in an
13 audio-visual format (i.e., a recorded video). The training will be conducted and led by either
14 the doctoral investigator or the two clinical nurses, and attendance will be recorded. All the
15 participants will be asked to perform the tai chi movements in front of the trainers (i.e., return
16 demonstration) to make sure that they are correctly performing each movement of the tai chi
17 exercise. In addition, the participants will be tested by the trainers during the last training
18 session to ensure that they have correctly performed the tai chi movements (via return
19 demonstration).

20 The intervention sessions will be 60 minutes and will be comprised of the following
21 components: a 10-minute warm-up, 25 to 30 minutes of easy 8 form tai chi practising, and a
22 10-minute cool-down. During each session, the participants will also have a 10-minute break
23 to rest. The tai chi intervention protocol was adapted in clinical practice to develop a
24 personalized intervention that will be tailored to the participants' convenience and preference
25 regarding the time and venue of the intervention. Details of the tai chi protocol are presented in
26 a methodological paper [24]. A specially designed exercise log will be provided to the
27 participants to record information related to their tai chi practice immediately after tai chi
28 practising each time, such as duration and frequency of practising tai chi, as well as any
29 potential adverse reactions related to tai chi, such as dizziness, knee pain, musculoskeletal
30 aches and pains, etc. The exercise logs will be returned to the research assistants on the date
31 of the participants' treatment or follow-up appointment at the hospital. To enhance the
32 participants' adherence to the tai chi intervention, the research assistants will conduct
33 telephone follow-ups every week to remind them to practise their tai chi and to collect
34 information on any potential adverse reactions related to the tai chi intervention.

35 ***Control group***

36 The participants allocated to the control group will receive a standard care package, which
37 will be a booklet on the self-management of cancer symptoms. This booklet will offer basic
38 knowledge and management strategies regarding FSDSC management in BC patients during
39 or after chemotherapy treatment. All the information listed in this booklet will be
40 comprehensively adapted from relevant national guidelines developed by professional
41 associations in cancer care and government health department websites, including the
42 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
43 (the NCCN Guidelines) [25] and the Department of Health – Government of Western

1 Australia [26]. Research evidence in published peer-reviewed articles will also be cited as
2 supporting information for the booklet's development [2, 27-29]. Additionally, the
3 participants will be asked to refrain from practising any exercises related to TCE during the
4 study, with reminders at all assessment time points. On completion of the pilot RCT, the
5 participants in the control group will have an opportunity to receive the tai chi training from
6 the study team.

7 ***Outcome measurements and follow-up***

8 The outcome measurements for this pilot RCT will include three categories, namely, baseline
9 assessments, feasibility and acceptability outcomes, and clinical outcomes. The feasibility and
10 acceptability outcomes will be the primary outcomes, while the clinical outcomes will be the
11 secondary outcomes. All the outcomes and follow-ups will be conducted by the two research
12 assistants.

13 ***Demographic and clinical characteristics of the participants***

14 A self-designed demographic and clinical data form will be employed to collect the
15 participants' socio-demographic data (e.g., age, education background, employment status,
16 marital status, and household income) and medical history (e.g., date of diagnosis, the current
17 stage of BC, and date and type of treatment) at baseline (T1).

18 ***Primary outcomes: Feasibility and acceptability***

19 **(1)** The feasibility assessment of subject recruitment and the follow-up process will include:
20 **(a)** the time that was taken to recruit the planned sample size of participants; **(b)** referral rate –
21 the number of referrals made by clinicians in different departments and hospitals divided by
22 all referrals; **(c)** recruitment rate – the number of subjects who enrolled in the study divided
23 by all subjects eligible for enrolment; **(d)** retention rate – the number of subjects who
24 completed the study divided by all subjects who enrolled in the study; **(e)** dropout rate – the
25 number of subjects who dropped out after randomization divided by all subjects who enrolled
26 in the study; and **(f)** feedback from the dropout subjects to identify their reasons for dropping
27 out. The feasibility of recruitment and follow-up process outcomes will be collected from
28 baseline (T1) to the completion of the intervention (T2).

29 **(2)** The feasibility assessment of the outcome measures will include the percentage of missing
30 values for each item of the scales used – the Brief Fatigue Inventory (BFI), the Pittsburgh
31 Sleep Quality Index (PSQI), the Hospital Anxiety and Depression Scale (HADS), and the
32 Functional Assessment of Cancer Therapy-Breast (FACT-B) – at baseline (T1), immediately
33 after the intervention (T2), and four weeks after completion of the intervention (T3).

34 **(3)** The feasibility and acceptability of the intervention will include: **(a)** adherence rates – the
35 number of tai chi sessions practised divided by the total number of sessions required; **(b)** the
36 participants' feedback on and satisfaction with the intervention using a self-designed feedback
37 form; **(c)** records of adverse events associated with tai chi, which will be obtained from the
38 exercise logs; and **(d)** the number of participants who completed the exercise log. The
39 feasibility and acceptability of the intervention will be assessed immediately after the
40 intervention (T2).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *Secondary outcomes: Fatigue, sleep disturbance, depression, and QoL*

2 The fatigue, sleep disturbance, depression, and QoL of the BC patients as the secondary
3 outcomes will be measured at T1, T2, and T3 using the BFI, the PSQI, the HADS, and the
4 FACT-B.

5 **(1) Fatigue:** The participants' severity of fatigue and cancer-related fatigue in daily
6 functioning will be measured using the BFI. The BFI has nine items, with higher scores
7 corresponding to more severe fatigue [30, 31]. The Chinese version of the BFI has excellent
8 internal consistency reliability (Cronbach's alpha from 0.90 to 0.92), as well as construct
9 validity and convergent validity [32].

10 **(2) Sleep disturbance:** The participants' sleep quality and disturbance will be assessed using
11 the PSQI. This questionnaire has seven domains: sleep latency, habitual sleep efficiency,
12 subjective sleep quality, sleep duration, use of sleeping medication, sleep disturbance, and
13 daytime dysfunction [33]. A total score will be calculated from the sum of the seven domains'
14 scores. A higher total score indicates poorer sleep quality. The Chinese version of the PSQI has
15 been demonstrated to be a reliable and valid scale, and it has been widely utilized among
16 cancer patients [34].

17 **(3) Depression:** The HADS will be used to assess the participants' depression. The cut-off
18 scores have been classified and labelled as 0 to 7 for "normal", 8 to 10 for "mild", 11 to 15
19 for "moderate", and ≥ 16 for "severe" [35]. As a reliable and valid tool for measuring
20 depression, the HADS has been widely utilized among Chinese cancer patients, with
21 well-documented psychometric properties [36].

22 **(4) Quality of life:** The FACT-B will be adopted to assess the participants' QoL. A higher
23 score demonstrates better QoL. The FACT-B is available in a simplified Chinese version,
24 with adequate psychometric properties reported among patients with BC [37].

25
26 ***Data management***

27 The doctoral investigator and one of the research assistants will enter all the collected data
28 into a computer with a double data entry approach. To ensure that there are no discrepancies
29 or coding errors after running descriptive and inferential statistics, data cleaning will be
30 conducted before data analysis [38]. First, the datasets will be checked against the paper
31 recordings of raw data to ensure that the data coding is correct. Then, double-checking will be
32 undertaken by the other research assistant to ensure accuracy. All electronic data will be
33 retained in a compressed folder using password-protected access systems, and all hard copies
34 of the materials will be retained in a cabinet at the study sites. Storage and disposal of
35 research data hard copies will strictly follow the regulations and policies of the lead
36 investigator's institution and the study sites, including the Charles Darwin University
37 Research Data Management Guide.

38
39 ***Data analysis***

40 Statistical analyses will be conducted using IBM SPSS Statistics for Windows, version 24.0
41 (IBM Corp., Armonk, NY, USA). The intention-to-treat (ITT) principle will be utilized for

1 the management of missing data. Effect sizes (ES) of between-group comparisons will be
2 estimated using Cohen's *d* [39]. The chi-squared test or Fisher's exact test will be used to
3 examine the comparisons between the control and intervention groups for categorical
4 variables (e.g., education background, referral rate, retention rate, etc.). An independent t-test
5 or the Mann-Whitney U test will be utilized for the continuous variables (e.g., age, household
6 income, etc.). The Generalized Estimating Equation (GEE) model will be performed for
7 repeated multivariate analysis between the two study groups for the total scores and domain
8 scores of the BFI, the PSQI, the HADS, and the FACT-B. The significance level to identify
9 statistical differences will be $p < 0.05$.

10 **Patient and public involvement**

11 No patient was involved in the study design or any other part of this protocol.

12 **Ethics and dissemination**

13 This study was registered at ClinicalTrials.gov (identifier NCT04190342) before its
14 commencement. The study has been approved by the Human Research Ethics Committee at
15 Charles Darwin University (H19094), the Clinical Trial Ethics Committee at the Affiliated
16 Hospital of Southwest Medical University (KY2019133), and the Clinical Trial Ethics
17 Committee at the Affiliated Hospital of Putian University (201932). The abstract of this study
18 has been submitted to Sigma's 32nd International Nursing Research Congress for presentation
19 in 2021. The results of the trial will be published in peer-reviewed scientific journals.

20 **Discussion**

21 As one of the most common symptom clusters in BC patients, the FSDSC can significantly
22 deteriorate patients' QoL and daily functioning [40, 41]. An increasing number of studies
23 have demonstrated that tai chi has beneficial effects on symptom management in cancer
24 patients; however, almost all the studies focused on individual symptoms only, such as fatigue,
25 sleep disturbance, or depression [42-44]. No study has ever been performed to investigate the
26 role of tai chi in managing symptom clusters in the BC population. This highlights a great
27 need to explore the effects of tai chi on the FSDSC in BC patients. Given that the patients will
28 have already experienced fatigue upon enrolment in this pilot RCT, lengthy and complicated
29 tai chi movements will be avoided. Easy 8 form tai chi, a traditional Chinese mind-body
30 exercise with only eight simple movements, is an appropriate intervention for FSDSC
31 management as it is easy to learn, is less energy-consuming, and requires no specific
32 equipment [45, 46].

33 This study has some strengths. According to the Medical Research Council Framework for
34 Developing and Evaluating Complex Interventions, the feasibility and acceptability of a
35 proposed intervention and research methodological procedures should be fully examined prior
36 to performing the full-scale study [47]. In this current pilot RCT, the feasibility and
37 acceptability of an easy 8 form tai chi intervention program will be assessed comprehensively
38 using a series of feasibility outcomes, including subject recruitment, intervention delivery,
39 and outcome assessments. A comprehensive assessment will promote the refinement of the
40 intervention protocol for the future main study. Furthermore, different from some current
41 non-pharmacological studies, the tai chi intervention protocol used in the current pilot RCT

1 will be evidence-based and rigorously developed based on systematic review evidence and
2 recommendations [48-56]; TCE principles, theories [57, 58], and practice standards [46, 59];
3 the characteristics of cancer-related symptoms; and the consensus of an expert panel. In
4 addition, an FSDSC self-management education booklet will be designed and provided to the
5 participants in both the intervention and control groups. The information listed in this booklet
6 will be comprehensively adapted from relevant national guidelines, professional bodies, and
7 research evidence in published peer-reviewed articles. The self-management education
8 booklet will be used as an enhanced care component to improve the patients' knowledge and
9 relevant coping strategies for FSDSC management. Finally, a safety assessment of the tai chi
10 protocol for cancer patients will be set as one of the feasibility outcomes, which has rarely
11 been measured in existing tai chi interventional studies. Although tai chi is a non-invasive
12 intervention that is generally regarded as a relatively safe approach, the exercise program
13 might still contribute to some minor adverse events such as a lumbar sprain, musculoskeletal
14 aches and pains, dizziness, knee pain, etc. [60]. Therefore, any potential adverse events
15 related to practising tai chi will be monitored and reported in the exercise log.

16 This study also has some limitations. Given the limited study sites, the study sample in this
17 study may not offer a completely representative sample of BC patients who are experiencing
18 the FSDSC. Due to the visible nature of the tai chi intervention, the blinding of the
19 participants and the tai chi instructor cannot be performed in this study, which might increase
20 the risk of detection bias during the study's implementation, although the outcome assessors
21 will be blinded to the intervention allocation. The lack of long-term follow-up to assess the
22 ongoing effects of tai chi might be another limitation, but this can be considered in the future
23 full-scale RCT as one of the main study outcomes.

24
25 This study will utilize a rigorously designed RCT to assess the feasibility and preliminary
26 effects of an evidence-based tai chi program for alleviating the FSDSC in BC patients. The
27 convenience of the tai chi for the self-management of the FSDSC may provide BC patients,
28 healthcare professionals, and policymakers with further guidance in FSDSC management in
29 the long run. Furthermore, the results of this trial will contribute to a future multi-centre
30 large-scale main RCT to further conclude the research evidence on the effects and safety of
31 tai chi for FSDSC management in BC patients.

32 **Trial status**

33 The study began in May 2020. Data collection and analysis is ongoing.

34 **Funding**

35 This trial was funded by the Australian Government Research Training Program (RTP)
36 scholarship, and the Award/Grant number is not applicable.

37 **Conflict of interest**

38 No conflict of interest regarding the publication of this paper was declared.

39 **Authors' contributions**

40 **Yao LQ:** study conception and design, trial organization, administration and coordination,
41 quality assurance, and manuscript drafting and revision; **Tan JY:** study conception and design,

1
2
3 1 study procedure supervision, and manuscript revision; **Turner C**: study conception and
4 design, study procedure supervision, and manuscript revision; **Wang T**: study design, study
5 procedure supervision, and manuscript revision.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. The schedule of trial enrolment, interventions, and assessments

	Study Period				
	Before Enrolment (0 weeks)	Intervention Period (1-8 weeks)	End of Intervention (8 weeks)	Follow-up Period (9-12 weeks)	End of Follow-up (12 weeks)
Inclusion/exclusion criteria	×				
Informed consent	×				
Demographic characteristics	×				
Randomization and allocation	×				
Feasibility of recruitment and follow-up process	×		×	×	×
Feasibility assessment of the outcome measures	×		×		×
Feasibility and acceptability of the intervention		×			
BFI	×		×		×
HADS	×		×		×
PSQI	×		×		×
FACT-B	×		×		×
Safety measurement		×			

Figure 1. CONSORT flowchart of the study**References**

- [1] Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2019 with focus on breast cancer. *Ann Oncol*. 2019 May 1;30(5):781-87. doi: 10.1093/annonc/mdz051
- [2] Jain S, Boyd C, Fiorentino L, Khorsan R, Crawford C. Are there efficacious treatments for treating the fatigue-sleep disturbance-depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL(©)). *Breast Cancer (Dove Med Press)*. 2015 Sep 2;7:267-91. doi: 10.2147/BCTT.S25014
- [3] Hsu HT, Lin KC, Wu LM, Juan CH, Hou MF, Hwang SL, Liu Y, Dodd MJ. Symptom cluster trajectories during chemotherapy in breast cancer outpatients. *J Pain Symptom Manage*. 2017 Jun;53(6):1017-25. doi: 10.1016/j.jpainsymman.2016.12.354
- [4] Liu L, Rissling M, Natarajan L, Fiorentino L, Mills PJ, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S. The longitudinal relationship between fatigue and sleep in breast cancer patients undergoing chemotherapy. *Sleep*. 2012 Feb 1;35(2):237-45. doi: 10.5665/sleep.1630
- [5] Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. *Oncol Nurs Forum*. 2001 Apr;28(3):465-70.
- [6] Aktas A, Kirkova J, Walsh D, Karafa M, Nair A, Schleckman E. The psychometric properties of cancer multi-symptom assessment instruments: a comprehensive review. *J Pain Symptom Manage*. 2012;43(2):334-5.
- [7] Ho SY, Rohan KJ, Parent J, Tager FA, McKinley PS. A longitudinal study of depression, fatigue, and sleep disturbances as a symptom cluster in women with breast cancer. *J Pain Symptom Manage*. 2015 Apr;49(4):707-15. doi: 10.1016/j.jpainsymman.2014.09.009
- [8] Kim HJ, Barsevick AM, Beck SL, Dudley W. Clinical subgroups of a psychoneurologic symptom cluster in women receiving treatment for breast cancer: a secondary analysis. *Oncol Nurs Forum*. 2012 Jan;39(1):E20-30. doi: 10.1188/12.ONF.E20-E30
- [9] Hökkä M, Kaakinen P, Pölkki T. A systematic review: non-pharmacological interventions in treating pain in patients with advanced cancer. *J Adv Nurs*. 2014 Sep;70(9):1954-69. doi: 10.1111/jan.12424
- [10] Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with prostate cancer: a systematic review of non-pharmacological interventions. *Int J Nurs Pract*. 2014 Oct;20(5):549-60. doi: 10.1111/ijn.12211
- [11] Yin C, Buchheit TE, Park JJ. Acupuncture for chronic pain: an update and critical overview. *Curr Opin Anaesthesiol*. 2017 Oct;30(5):583-92. doi: 10.1097/ACO.0000000000000501
- [12] McKernan LC, Finn MTM, Patterson DR, Williams RM, Jensen MP. Clinical hypnosis for chronic pain in outpatient integrative medicine: an implementation and training model. *J Altern Complement Med*. 2020 Feb;26(2):107-12. doi: 10.1089/acm.2019.0259
- [13] Charalambous A, Giannakopoulou M, Bozas E, Marcou Y, Kitsios P, Paikousis L. Guided

- imagery and progressive muscle relaxation as a cluster of symptoms management intervention in patients receiving chemotherapy: a randomized control trial. *PLoS One*. 2016 Jun 24;11(6):e0156911. doi: 10.1371/journal.pone.0156911
- [14] Lopez G, Liu W, Milbury K, Spelman A, Wei Q, Bruera E, Cohen L. The effects of oncology massage on symptom self-report for cancer patients and their caregivers. *Support Care Cancer*. 2017 Dec;25(12):3645-50. doi: 10.1007/s00520-017-3784-7
- [15] Nguyen LT, Yates P, Annoussamy LC, Truong TQ. The effectiveness of non-pharmacological interventions in the management of symptom clusters in adult cancer patients: a systematic review protocol. *JBISRIR*. 2016 Apr;14(4):49-59. doi: 10.11124/JBISRIR-2016-2476
- [16] Zou L, Wang H, Xiao Z, Fang Q, Zhang M, Li T, Du G, Liu Y. Tai chi for health benefits in patients with multiple sclerosis: a systematic review. *PLoS One*. 2017 Feb 9;12(2):e0170212. doi: 10.1371/journal.pone.0170212
- [17] Jahnke R, Larkey L, Rogers C, Etnier J, Lin F. A comprehensive review of health benefits of qigong and tai chi. *Am J Health Promot*. 2010 Jul-Aug;24(6):e1-e25. doi: 10.4278/ajhp.081013-LIT-248
- [18] Irwin MR, Olmstead R, Carrillo C, Sadeghi N, Nicassio P, Ganz PA, Bower JE. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. *J Clin Oncol*. 2017 Aug 10;35(23):2656-65. doi: 10.1200/JCO.2016.71.0285. Epub 2017 May 10. Erratum in: *J Clin Oncol*. 2017 Dec 20;35(36):4096.
- [19] McQuade JL, Prinsloo S, Chang DZ, Spelman A, Wei Q, Basen-Engquist K, Harrison C, Zhang Z, Kuban D, Lee A, Cohen L. Qigong/tai chi for sleep and fatigue in prostate cancer patients undergoing radiotherapy: a randomized controlled trial. *Psychooncology*. 2017 Nov;26(11):1936-43. doi: 10.1002/pon.4256
- [20] Zhang LL, Wang SZ, Chen HL, Yuan AZ. Tai chi exercise for cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial. *J Pain Symptom Manage*. 2016 Mar;51(3):504-11. doi: 10.1016/j.jpainsymman.2015.11.020
- [21] Browne RH. On the use of a pilot sample for sample size determination. *Stat Med*. 1995;14(17):1933-40.
- [22] Hertzog MA. Considerations in determining sample size for pilot studies. *Res Nurs Health*. 2008 Apr;31(2):180-91. doi: 10.1002/nur.20247
- [23] Campo RA, O'Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY. Feasibility and acceptability of a tai chi chih randomized controlled trial in senior female cancer survivors. *Integr Cancer Ther*. 2013 Nov;12(6):464-74. doi: 10.1177/1534735413485418
- [24] Yao LQ, Tan JY, Turner C, Wang T. Development and validation of a tai chi intervention protocol for managing the fatigue-sleep disturbance-depression symptom cluster in female breast cancer patients. *Complement Ther Med* (in press).
- [25] NCCN Cancer-Related Fatigue Panel (2018). National Comprehensive Cancer Network

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Clinical practice guidelines in oncology. Cancer-Related Fatigue, version 2.

[26] Department of Health at the Government of Western Australia. Retrieved from <https://www.health.gov.au/resources>.

[27] Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C; National Comprehensive Cancer Network. Cancer-related fatigue, Version 2.2015. *J Natl Compr Canc Netw*. 2015 Aug;13(8):1012-39. doi: 10.6004/jnccn.2015.0122

[28] Berger AM, Mitchell SA, Jacobsen PB, Pirl WF. Screening, evaluation, and management of cancer-related fatigue: ready for implementation to practice? *CA Cancer J Clin*. 2015 May-Jun;65(3):190-211. doi: 10.3322/caac.21268

[29] Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. *J Clin Oncol*. 2012 Apr 10;30(11):1187-96. doi: 10.1200/JCO.2011.39.7372

[30] Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. *Cancer*. 1999 Mar 1;85(5):1186-96. doi: 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cnrc24>3.0.co;2-n

[31] Nunes AF, Bezerra CO, Custódio JDS, Friedrich CF, Oliveira IS, Lunardi AC. Clinimetric properties of the brief fatigue inventory applied to oncological patients hospitalized for chemotherapy. *J Pain Symptom Manage*. 2019 Feb;57(2):297-303. doi: 10.1016/j.jpainsymman.2018.10.508

[32] Wang XS, Hao XS, Wang Y, Guo H, Jiang YQ, Mendoza TR, Cleeland CS. Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). *J Pain Symptom Manage*. 2004 Apr;27(4):322-32. doi: 10.1016/j.jpainsymman.2003.09.008

[33] Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res*. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4

[34] Tsai PS, Wang SY, Wang MY, Su CT, Yang TT, Huang CJ, Fang SC. Psychometric evaluation of the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia and control subjects. *Qual Life Res*. 2005 Oct;14(8):1943-52. doi: 10.1007/s11136-005-4346-x

[35] Smith RP, Zigmond AS. *The Hospital Anxiety and Depression Scale Manual*. Windsor: NFER—Nelson, 1994.

[36] Wang W, Chair SY, Thompson DR, Twinn SF. A psychometric evaluation of the Chinese version of the Hospital Anxiety and Depression Scale in patients with coronary heart disease. *J Clin Nurs*. 2009 Jul;18(13):1908-15. doi: 10.1111/j.1365-2702.2008.02736.x

[37] Wan C, Zhang D, Yang Z, Tu X, Tang W, Feng C, Wang H, Tang X. Validation of the simplified Chinese version of the FACT-B for measuring quality of life for patients with breast

- 1
2
3 cancer. *Breast Cancer Res Treat*. 2007 Dec;106(3):413-18. doi: 10.1007/s10549-007-9511-1
- 4 [38] Portney LG, Watkins MP. *Foundations of Clinical Research: Applications to Practice* (Vol. 5
6 892). Upper Saddle River, NJ: Pearson/Prentice Hall, 2009.
- 7 [39] Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*. Hillsdale, NJ: Lawrence
8 Erlbaum Associates, 1988.
- 9 [40] Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G. The relationship between
10 depression and physical symptom burden in advanced cancer. *BMJ Support Palliat Care*. 2015
11 Dec;5(4):381-8. doi: 10.1136/bmjspcare-2012-000380
- 12 [41] Oh H, Seo Y, Jeong H, Seo W. The identification of multiple symptom clusters and their
13 effects on functional performance in cancer patients. *J Clin Nurs*. 2012 Oct;21(19-20):2832-42.
14 doi: 10.1111/j.1365-2702.2011.04057.x
- 15 [42] Qiang WM, Dong FQ, Yan L, et al. Comparison of two different exercise programs in breast
16 cancer patients after postoperative adjuvant chemotherapy. *Chin J Nurs*. 2011;46:537e540.
- 17 [43] Jiang MY. Influence of shadowboxing on improving cancer-related fatigue and sleeping
18 quality of patients with advanced lung cancer. *Chin Nurs Res*. 2013;27:420e421.
- 19 [44] Larkey LK, Roe DJ, Weihs KL, Jahnke R, Lopez AM, Rogers CE, Oh B, Guillen-Rodriguez
20 J. Randomized controlled trial of qigong/tai chi easy on cancer-related fatigue in breast cancer
21 survivors. *Ann Behav Med*. 2015 Apr;49(2):165-76. doi: 10.1007/s12160-014-9645-4. PMID:
22 25124456; PMCID: PMC4329282.
- 23 [45] Tadros G, Ormerod S, Dobson-Smyth P, Gallon M, Doherty D, Carryer A, Oyeboode J,
24 Kingston P. The management of behavioural and psychological symptoms of dementia in
25 residential homes: does tai chi have any role for people with dementia? *Dementia (London)*. 2013
26 Mar;12(2):268-79. doi: 10.1177/1471301211422769
- 27 [46] Li F, Fisher KJ, Harmer P, Shirai M. A simpler eight-form easy tai chi for elderly adults. *J*
28 *Aging Phys Act*. 2003;11(2):206-18.
- 29 [47] Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research
30 Council Guidance. Developing and evaluating complex interventions: the new Medical Research
31 Council guidance. *BMJ*. 2008 Sep 29;337:a1655. doi: 10.1136/bmj.a1655
- 32 [48] Ma HL, Tan JY, Yang LH, Tao L, Liao QJ. Current evidence on traditional Chinese exercises
33 for cancer-related fatigue: a quantitative synthesis of randomized controlled trials. *Eur J Integr*
34 *Med*. 2016;8(5):707-14. doi:10.1016/j.eujim.2016.05.007
- 35 [49] Wayne PM, Lee MS, Novakowski J, Osypiuk K, Ligibel J, Carlson LE, Song R. Tai chi and
36 qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis. *J*
37 *Cancer Surviv*. 2018 Apr;12(2):256-67. doi: 10.1007/s11764-017-0665-5
- 38 [50] Song S, Yu J, Ruan Y, Liu X, Xiu L, Yue X. Ameliorative effects of tai chi on cancer-related
39 fatigue: a meta-analysis of randomized controlled trials. *Support Care Cancer*. 2018
40 Jul;26(7):2091-102. doi: 10.1007/s00520-018-4136-y
- 41 [51] Van Vu D, Molassiotis A, Ching SSY, Le TT. Effects of Qigong on symptom management in
42 cancer patients: a systematic review. *Complement Ther Clin Pract*. 2017 Nov;29:111-21. doi:

1
2
3
4
10.1016/j.ctcp.2017.09.005

5 [52] Xiang Y, Lu L, Chen X, Wen Z. Does tai chi relieve fatigue? A systematic review and
6 meta-analysis of randomized controlled trials. *PLoS One*. 2017 Apr 5;12(4):e0174872. doi:
7 10.1371/journal.pone.0174872

8 [53] Yao LQ, Tan JY, Turner C, Wang T, Liu XL. Traditional Chinese exercise for cancer-related
9 sleep disturbance: a systematic review and descriptive analysis of randomized clinical trials.
10 *Complement Ther Clin Pract*. doi:10.1016/j.ctcp.2020.101197

11 [54] Zeng Y, Xie X, Cheng ASK. Qigong or tai chi in cancer care: an updated systematic review
12 and meta-analysis. *Curr Oncol Rep*. 2019 Apr 6;21(6):48. doi: 10.1007/s11912-019-0786-2

13 [55] Ni X, Chan RJ, Yates P, Hu W, Huang X, Lou Y. The effects of tai chi on quality of life of
14 cancer survivors: a systematic review and meta-analysis. *Support Care Cancer*. 2019
15 Oct;27(10):3701-16. doi: 10.1007/s00520-019-04911-0

16 [56] Hilfiker R, Meichtry A, Eicher M, Nilsson Balfe L, Knols RH, Verra ML, Taeymans J.
17 Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during
18 or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis.
19 *Br J Sports Med*. 2018 May;52(10):651-8. doi: 10.1136/bjsports-2016-096422

20 [57] Bower JE, Irwin MR. Mind-body therapies and control of inflammatory biology: a
21 descriptive review. *Brain Behav Immun*. 2016 Jan;51:1-11. doi: 10.1016/j.bbi.2015.06.012

22 [58] Larkey L, Jahnke R, Etnier J, Gonzalez J. Meditative movement as a category of exercise:
23 implications for research. *J Phys Act Health*. 2009 Mar;6(2):230-8. doi: 10.1123/jpah.6.2.230

24 [59] Committee of Chinese Sports College Textbook. *Chinese Wushu Textbook (Part I)*. People's
25 Sports Publishing House of China: Beijing, 2003.

26 [60] Jia X, Jiang C, Tao J, Li Y, Zhou Y, Chen LD. Effects of core strength training combined
27 with tai chi chuan for the musculoskeletal system and cardiopulmonary function in older adults: a
28 study protocol for a randomized controlled trial. *Medicine (Baltimore)*. 2018 Aug;97(35):e12024.
29 doi: 10.1097/MD.00000000000012024

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1. A CONSORT flowchart of the study



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	<u>Page 1</u>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	<u>Page 2</u>
	2b	All items from the World Health Organization Trial Registration Data Set	<u>Not applicable</u>
Protocol version	3	Date and version identifier	<u>Page 2</u>
Funding	4	Sources and types of financial, material, and other support	<u>Page 10</u>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	<u>Page 11</u>
	5b	Name and contact information for the trial sponsor	<u>Page 1</u>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	<u>Page 11</u>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	<u>Page 8</u>

1 Introduction

2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	<u>Page 3</u>
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	<u>Page 3</u>
7				
8	Objectives	7	Specific objectives or hypotheses	<u>Page 3</u>
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	<u>Page 3-4</u>
12				
13				
14	Methods: Participants, interventions, and outcomes			
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	<u>Page 4</u>
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	<u>Page 4</u>
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	<u>Page 6-7</u>
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	<u>Not applicable</u>
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	<u>Page 6-7</u>
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>Page 6-7</u>
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	<u>Page 7-8</u>
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation	
35			(eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits	<u>Page 12</u>
39			for participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>Page 4</u>
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>Page 4-5</u>
5				
6	Methods: Assignment of interventions (for controlled trials)			
7	Allocation:			
8				
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>Page 5</u>
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>Page 5</u>
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>Page 5</u>
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>Page 5</u>
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>Page 5</u>
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>Page 7-8</u>
34				
35				
36				
37				
38		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	<u>Page 8</u>
39				
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	<u>Page 8</u>
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	<u>Page 8-9</u>
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	<u>Page 8-9</u>
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	<u>Page 8-9</u>
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>Page 8</u>
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>Page 8</u>
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>Page 7</u>
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>Page 5</u>
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>Page 9</u>
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>Not applicable</u>
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>Page 4 & 5</u>
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>Not applicable</u>
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>Page 8</u>
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>Page 10</u>
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>Page 8</u>
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>Not applicable</u>
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>Page 9</u>
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	<u>Not applicable</u>
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>Not applicable</u>
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>Supplementary file</u>
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>Not applicable</u>
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.